index,title,abstract,Master Ref#,PubMed ID,Journal,Primary Author,Publication Year,Volume / Issue,Pages,Priority Journal,PubMed ID:,Full Reference:,"Study Outcome ($/QALY, $/DALY, Both):",Study Country:,Disease Classification:,Intervention Type(s):,Intervention Phrase vs. Comparator Phrase:,Target Characteristics:,Max Target Age:,Min Target Age:,Target Genders:,Review:,Time Horizon:,Discounting Rate (Costs):,Discounting Rate (QALYs):,Incremental Cost-Effectiveness Ratio (Original currency and year):,Currency Country:,Currency Year:,Incremental Cost-Effectiveness Ratio (Converted to current $USD):
12201,"Cost-utility analysis of neonatal screening program, shiraz university of medical sciences, shiraz, iran, 2010","OBJECTIVE: The most important cause of infant mortality during the first month of life is related to congenital abnormalities. Nevertheless, timely diagnosis of these diseases can reduce the severity of their effects. The present study aimed to investigate the cost-effectiveness of the neonatal screening program in Fars Province, Iran. METHODS: In this study, costs of executing the screening programs, treatment of the diagnosed cases, treatment of affected, non-screened individuals, quality of life, and incremental cost-effectiveness ratios were measured in two study groups. FINDINGS: Performing the screening programs for phenylketonuria, congenital hypothyroidism, galactosemia, and favism resulted in respectively $3386, $13078, $19641, and $1088 saving per patient. Overall, the study results revealed the cost-effectiveness of execution of the neonatal screening program. CONCLUSION: Neonatal screening program is one of the health interventions which lead to long-term beneficial outcome for the patients, financial saving for the society, and improvement of the patients' quantity as well as quality of life.",2013-01-15202,24800006,Iran J Pediatr,Nahid Hatam,2013,23 / 5,493-500,No,24800006,"Nahid Hatam; Samad Shirvani; Mehdi Javanbakht; Mehrdad Askarian; Mohsen Rastegar; Cost-utility analysis of neonatal screening program, shiraz university of medical sciences, shiraz, iran, 2010, Iran J Pediatr, ; 23(5):2008-2142; 493-500",QALY,Iran,Not Stated,Not Stated,"Screening, Congenital hypothyroidism vs. None",Not Stated,18 Years,Not Stated,"Female, Male",Full,Lifetime,3.00,3.00,-137350.91,United States,2010,-163022
12202,"Cost-utility analysis of neonatal screening program, shiraz university of medical sciences, shiraz, iran, 2010","OBJECTIVE: The most important cause of infant mortality during the first month of life is related to congenital abnormalities. Nevertheless, timely diagnosis of these diseases can reduce the severity of their effects. The present study aimed to investigate the cost-effectiveness of the neonatal screening program in Fars Province, Iran. METHODS: In this study, costs of executing the screening programs, treatment of the diagnosed cases, treatment of affected, non-screened individuals, quality of life, and incremental cost-effectiveness ratios were measured in two study groups. FINDINGS: Performing the screening programs for phenylketonuria, congenital hypothyroidism, galactosemia, and favism resulted in respectively $3386, $13078, $19641, and $1088 saving per patient. Overall, the study results revealed the cost-effectiveness of execution of the neonatal screening program. CONCLUSION: Neonatal screening program is one of the health interventions which lead to long-term beneficial outcome for the patients, financial saving for the society, and improvement of the patients' quantity as well as quality of life.",2013-01-15202,24800006,Iran J Pediatr,Nahid Hatam,2013,23 / 5,493-500,No,24800006,"Nahid Hatam; Samad Shirvani; Mehdi Javanbakht; Mehrdad Askarian; Mohsen Rastegar; Cost-utility analysis of neonatal screening program, shiraz university of medical sciences, shiraz, iran, 2010, Iran J Pediatr, ; 23(5):2008-2142; 493-500",QALY,Iran,Not Stated,Not Stated,"Screening, Galactosemia vs. None",Not Stated,18 Years,Not Stated,"Female, Male",Full,Lifetime,3.00,3.00,-21087,United States,2010,-25028.19
12203,"Cost-utility analysis of neonatal screening program, shiraz university of medical sciences, shiraz, iran, 2010","OBJECTIVE: The most important cause of infant mortality during the first month of life is related to congenital abnormalities. Nevertheless, timely diagnosis of these diseases can reduce the severity of their effects. The present study aimed to investigate the cost-effectiveness of the neonatal screening program in Fars Province, Iran. METHODS: In this study, costs of executing the screening programs, treatment of the diagnosed cases, treatment of affected, non-screened individuals, quality of life, and incremental cost-effectiveness ratios were measured in two study groups. FINDINGS: Performing the screening programs for phenylketonuria, congenital hypothyroidism, galactosemia, and favism resulted in respectively $3386, $13078, $19641, and $1088 saving per patient. Overall, the study results revealed the cost-effectiveness of execution of the neonatal screening program. CONCLUSION: Neonatal screening program is one of the health interventions which lead to long-term beneficial outcome for the patients, financial saving for the society, and improvement of the patients' quantity as well as quality of life.",2013-01-15202,24800006,Iran J Pediatr,Nahid Hatam,2013,23 / 5,493-500,No,24800006,"Nahid Hatam; Samad Shirvani; Mehdi Javanbakht; Mehrdad Askarian; Mohsen Rastegar; Cost-utility analysis of neonatal screening program, shiraz university of medical sciences, shiraz, iran, 2010, Iran J Pediatr, ; 23(5):2008-2142; 493-500",QALY,Iran,Not Stated,Not Stated,"Screening, Favism vs. None",Not Stated,18 Years,Not Stated,"Female, Male",Full,Lifetime,3.00,3.00,-390.25,United States,2010,-463.19
12204,A value-based analysis of hemodynamic support strategies for high-risk heart failure patients undergoing a percutaneous coronary intervention,"BACKGROUND: The economic burden of heart disease is heavy and growing. As advanced technologies for treating heart disease become available, decision makers need to be able to assess the relative value of such options against existing standards of care. OBJECTIVES: To compare the clinical and economic benefits of a percutaneous ventricular assist device (pVAD) versus an intra-aortic balloon pump (IABP) observed during the 90-day duration of the PROTECT II clinical trial, and to supplement these findings with a simulation of the longer-term value of this technology through the use of a Markov model to estimate the incremental cost-effectiveness of a pVAD relative to an IABP, in terms of quality-adjusted life-years (QALYs). METHODS: Hospital bills were collected for patients enrolled in the PROTECT II trial who received hemodynamic support for high-risk percutaneous coronary intervention (PCI) provided by a pVAD (Impella 2.5) versus a conventional IABP during a 90-day episode of care (EOC). Length of stay, charges, and costs were analyzed for the index admissions, intensive care unit confinements, readmissions, and overall EOC. In addition, a probabilistic Markov model was used to project these parameters and their impact on a patient''s quality of life for up to 10 years in relation to a pVAD versus an IABP. RESULTS: Hospital costs for the index admission were lower for the IABP compared with the pVAD ($33,684 vs $47,667; P <.001), whereas readmission length of stay and costs were lower for the pVAD versus the IABP (5 days vs 7 days; and $11,007 vs $21,834, respectively; P <.001). The total 90-day hospital charges were similar for the pVAD and the IABP ($172,564 vs $172,758, respectively; P = .785); however, the total 90-day EOC cost was lower for the IABP than for the pVAD ($44,032 vs $53,171, respectively; P <.001). The median hospital days for the entire EOC were 7 days for the pVAD versus 9 days for the IABP (P = .008). Critical care stays were considerably shorter for a pVAD than for an IABP on readmissions (3.88 days vs 7.00 days; P = .145). Reduction in major adverse cardiovascular and cerebrovascular events resulted in a projected gain of 0.26 QALYs over 10 years, yielding an incremental cost-effectiveness ratio of $39,389/QALY. CONCLUSIONS: For high-risk patients with advanced heart failure undergoing PCI, the new pVAD reduced major adverse events, critical care and readmission length of stay, and readmission cost over the 90-day EOC, and was determined to be cost-effective over the long-term. These findings can assist decision makers in forming value-based judgments with regard to new hemodynamic support strategies.",2013-01-15243,24991349,Am Health Drug Benefits,David Gregory,2013,6 / 2,88-99,No,24991349,"David Gregory; Dennis J Scotti; Gregory de Lissovoy; Igor Palacios; Simon Dixon; Brijeshwar Maini; William O'Neill; A value-based analysis of hemodynamic support strategies for high-risk heart failure patients undergoing a percutaneous coronary intervention, Am Health Drug Benefits, ; 6(2):1942-2962; 88-99",QALY,United States of America,Not Stated,Not Stated,Percutaneous ventricular assist device (pVAD) vs. intra-aortic balloon pump (IABP),Not Stated,Not Stated,41 Years,"Female, Male",Full,10 Years,3.00,3.00,39389,United States,2009,47517.71
12205,Optimizing the Economic Impact of rtPA Use in a Stroke Belt State: The Case of South Carolina,"BACKGROUND: Stroke is the fourth leading cause of death in the United States, and its incidence is especially high in South Carolina. Recombinant tissue plasminogen activator (rtPA) has been given to patients with acute ischemic stroke since 1996 and has shown overall improved outcomes relative to patients who are not treated with rtPA. OBJECTIVE: A 1998 study by Fagan and colleagues reported the economic impact of the use of rtPA. The purpose of this current article is to present an updated economic analysis of the impact of rtPA. METHODS: In the current analysis, an updated estimate of the economic and health benefits of treatment with rtPA in South Carolina was provided using estimates of cost, incidence, and course of treatment from several data sources. The Markov model in the 1998 study was used as a guide in this current study; we sought to replicate the methodology, while providing updated economic figures and applying it to the state of South Carolina. We estimated the costs per 1000 patients who are eligible for treatment with rtPA compared with 1000 untreated patients, as well as routine medical practice and outcomes of quality-adjusted life-years (QALYs) and economic costs based on whether a patient was treated with rtPA or not. We calculated the number of stroke cases that would be treated with rtPA if the rate were to increase from 3% to 20%, using the most recent number of strokes in South Carolina and prorating for 5 years to estimate the total expected cost-savings with increased rtPA use. RESULTS: The results indicate that the use of rtPA in South Carolina accounts for a cost-savings of $3454 per treated patient over a 6-year period. The model estimates an increase of 0.425 QALYs (or 5.1 quality-adjusted months) of survival per patient treated with rtPA. Over the lifetime of a treated patient, the estimated cost-savings are $4084, with an accrued health benefit of 0.692 QALYs (or 8.3 quality-adjusted months). For every 100 patients treated with rtPA, there is a gain of 69.17 QALYs and of $408,419 over the lifetime of 100 treated patients with acute ischemic stroke. We calculated that the cost-savings gained by increasing the rtPA treatment rate in a state with a high incidence of stroke from the current 3% rate to an achievable 20% rate over a 5-year period would be $16,615,723. CONCLUSIONS: This new analysis demonstrates a significant savings associated with the use of rtPA for patients with stroke and provides great support for the increased systematic use of rtPA in the state of South Carolina for patients with acute ischemic stroke. For every additional 100 patients who are treated with rtPA in South Carolina, a robust savings supports the wider economic benefit that would be gained with an increased use of rtPA.",2013-01-15244,24991353,Am Health Drug Benefits,Abby Swanson Kazley,2013,6 / 4,155-63,No,24991353,"Abby Swanson Kazley; Kit N Simpson; Annie Simpson; Edward Jauch; Robert J Adams; Optimizing the Economic Impact of rtPA Use in a Stroke Belt State: The Case of South Carolina, Am Health Drug Benefits, ; 6(4):1942-2962; 155-63",QALY,United States of America,Not Stated,Not Stated,"Recombinant tissue plasminogen activator (rtPA), lifetime vs. None",Not Stated,Not Stated,68 Years,"Female, Male",Full,Lifetime,3.00,3.00,-5904.57,United States,2011,-6793.7
12206,Estimating the payoffs from cardiovascular disease research in Canada: an economic analysis,"BACKGROUND: Investments in medical research can result in health improvements, reductions in health expenditures and secondary economic benefits. These ""returns"" have not been quantified in Canada. Our objective was to estimate the return on cardiovascular disease research funded by public or charitable organizations. METHODS: Our primary outcome was the internal rate of return on cardiovascular disease research funded by public or charitable sources. The internal rate of return is the annual monetary benefit to the economy for each dollar invested in cardiovascular disease research. Calculation of the internal rate of return involved the following: measuring expenditures on cardiovascular disease research, estimating the health gains accrued from new treatments for cardiovascular disease, determining the proportion of health gains attributable to cardiovascular disease research and the time lag between research expenditures and health gains, and estimating the spillovers from public- or charitable-sector investments to other sectors of the economy. RESULTS: Expenditures by public or charitable organizations on cardiovascular disease research from 1981 to 1992 amounted to $392 million (2005 dollars). Health gains associated with new treatments from 1994 to 2005 (13-yr lag) amounted to 2.2 million quality-adjusted life-years. We calculated an internal rate of return of 20.6%. CONCLUSION: Canadians obtain relatively high health and economic gains from investments in cardiovascular disease research. Every $1 invested in cardiovascular disease research by public or charitable sources yields a stream of benefits of roughly $0.21 to the Canadian economy per year, in perpetuity.",2013-01-15264,25077108,CMAJ Open,Claire de Oliveira,2013,1 / 2,E83-90,No,25077108,"Claire de Oliveira; Hai V Nguyen; Harindra C Wijeysundera; William W L Wong; Gloria Woo; Paul Grootendorst; Peter P Liu; Murray D Krahn; Estimating the payoffs from cardiovascular disease research in Canada: an economic analysis, CMAJ Open, ; 1(2):2291-0026; E83-90",QALY,Canada,Not Stated,Not Stated,Cardiovascular disease research vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,Lifetime,Not Stated,Not Stated,9020.51,Canada,2005,9873.39
12207,Pharmacoeconomic analysis of paliperidone palmitate versus olanzapine pamoate for chronic schizophrenia in Norway,"OBJECTIVE: Paliperidone palmitate long-acting injection (PP-LAI) has recently been approved for treatment of chronic schizophrenia. Its cost-effectiveness has not been established. The objective was to compare direct costs and outcomes between PP-LAI and olanzapine pamoate (OLZ-LAI) in treating chronic schizophrenia in Norway from the perspective of the government payer. METHODS: We used a decision analytic model over a 1-year time horizon. Clinical inputs were derived from the literature and an expert panel; costs were taken from standard lists, adjusted to 2010 Norwegian kroner (NOK). Discounting was not done. Main outcomes included average cost per patient treated, hospitalisations, emergency room (ER) visits and quality-adjusted life years (QALYs). The pharmacoeconomic outcome was the incremental cost per QALY. Robustness was examined using one-way sensitivity analyses on critical variables and a 5000-iteration probabilistic Monte Carlo sensitivity analysis with all variables included. RESULTS: PP-LAI generated 0.845 QALY at a cost of 151 336 NOK of which 23% was due to drugs; 25% of patients were hospitalised and another 12% required ER visits. OLZ-LAI cost 174 351 NOK (21% due to drugs); patient outcomes included 0.844 QALY, 27% hospitalisations and 14% ER visits. PP-LAI dominated OLZ-LAI in the base case. The analysis was reasonably robust against variations in drug cost but sensitive to small changes in adherence and hospitalisation rates. Overall, PP-LAI was dominant over OLZ-LAI in 54.5% of simulations. Replacing OLZ-LAI with PP-LAI would be cost saving for the Norwegian healthcare system. CONCLUSION: PP-LAI was cost-effective compared with OLZ-LAI in treating patients with chronic schizophrenia in Norway but sensitive to changes in adherence and hospitalisation rates.",2013-01-17148,25287309,Acta Neuropsychiatr,Thomas R Einarson,2013,25 / 2,85-94,No,25287309,"Thomas R Einarson; Colin Vicente; Roman Zilbershtein; Charles Piwko; Christel N Bo; Hanna Pudas; Michiel E H Hemels; Pharmacoeconomic analysis of paliperidone palmitate versus olanzapine pamoate for chronic schizophrenia in Norway, Acta Neuropsychiatr, ; 25(2):1601-5215; 85-94",QALY,Norway,Not Stated,Not Stated,Paliperidone palmitate vs. Olanzapine pamoate,Not Stated,Not Stated,Not Stated,"Female, Male",Full,1 Year,Not Stated,Not Stated,-23015998,Norway,2010,-4525240.95
12208,Golimumab for the treatment of ankylosing spondylitis: a NICE single technology appraisal,"As part of the National Institute for Health and Clinical Excellence (NICE) single technology appraisal (STA) process, the Evidence Review Group (ERG) produced a report to comment on the clinical and cost effectiveness of golimumab (Simponi((R)), Merck Sharp & Dohme) for the treatment of ankylosing spondylitis (AS) relative to other comparators as presented in the manufacturer''s submission (MS) to NICE. The population was those with active disease who had not responded to conventional therapy. The specified comparators were conventional care and two other tumour necrosis factor alpha (TNF-alpha) inhibitors (adalimumab and etanercept). Outcomes to be considered were disease activity, functional capacity, disease progression, adverse effects of treatment and health-related quality of life (HR-QOL). There were no head-to-head trials comparing TNF-alpha inhibitors. The submission included one trial of golimumab versus placebo (the GO-RAISE trial) and additionally seven placebo-controlled randomized controlled trials (RCTs) of other TNF-alpha inhibitor agents (five with etanercept, and two with adalimumab). The results of these trials were generally a statistically significant improvement from each of the TNF-alpha inhibitors. A Bayesian mixed treatment comparison (MTC) showed there was generally overlap in the 95 % credible intervals (CrIs) between the TNF-alpha inhibitors. Exceptions included a greater risk of discontinuation of treatment for golimumab than for etanercept (relative risk [RR] 4.30; 95 % CrI 1.01-18.50). The cost-effectiveness analysis (CEA) compared all of these TNF-alpha inhibitors. Relative effectiveness was informed only by RR of response (proportion achieving at least a 50 % improvement in Bath AS Disease Activity Index [BASDAI] score; BASDAI50) from the MTC. In the base-case analysis, the incremental cost-effectiveness ratio (ICER) of golimumab versus conventional care was pound26,597 and adalimumab and etanercept were extendedly dominated by golimumab. The manufacturer concluded that golimumab is a cost-effective treatment option. Generally, the ERG agreed with the MTC analyses. The main problem was that the MS used data from one trial, which included a period of cross-over. The ERG found some problems with the CEA model, mainly that it did not allow for comparison of TNF-alpha inhibitor sequences and did not use MTC estimates for treatment discontinuation or adverse events (AEs). The ERG could not correct the sequencing problem, but re-ran the CEA with discontinuations and AEs estimated from the MTC and using the correct trial data. The results of the ERG analysis were that golimumab was extendedly dominated by etanercept, and the preferred treatment was either conventional treatment or etanercept, depending on the ICER threshold. Uncertainty was also substantial. NICE issued guidance (technology appraisal [TA] 233), which recommended golimumab according to the indications described in TA143 for etanercept and adalimumab, i.e. as first-line therapy among the TNF-alpha inhibitors unless patients are intolerant to one or both alternatives. Given the factors cited by NICE for their decision, the ERG recommends that there should be greater clarity in the NICE methods guidance on handling uncertainty in CEAs as well as the incorporation of benefit from process of care.",2013-01-19312,23580355,Pharmacoeconomics,Nigel Armstrong,2013,31 / 5,415-25,Yes,23580355,"Nigel Armstrong; Manuela Joore; Thea van Asselt; Kate Misso; Nathan Manning; Florian Tomini; Jos Kleijnen; Rob Riemsma; Golimumab for the treatment of ankylosing spondylitis: a NICE single technology appraisal, Pharmacoeconomics, ; 31(5):1179-2027; 415-25",QALY,United Kingdom,Not Stated,Not Stated,Golimumab vs. Standard/Usual Care- conventional treatment,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,Not Stated,Not Stated,26949.15,United Kingdom,2011,49744.97
12209,Golimumab for the treatment of ankylosing spondylitis: a NICE single technology appraisal,"As part of the National Institute for Health and Clinical Excellence (NICE) single technology appraisal (STA) process, the Evidence Review Group (ERG) produced a report to comment on the clinical and cost effectiveness of golimumab (Simponi((R)), Merck Sharp & Dohme) for the treatment of ankylosing spondylitis (AS) relative to other comparators as presented in the manufacturer''s submission (MS) to NICE. The population was those with active disease who had not responded to conventional therapy. The specified comparators were conventional care and two other tumour necrosis factor alpha (TNF-alpha) inhibitors (adalimumab and etanercept). Outcomes to be considered were disease activity, functional capacity, disease progression, adverse effects of treatment and health-related quality of life (HR-QOL). There were no head-to-head trials comparing TNF-alpha inhibitors. The submission included one trial of golimumab versus placebo (the GO-RAISE trial) and additionally seven placebo-controlled randomized controlled trials (RCTs) of other TNF-alpha inhibitor agents (five with etanercept, and two with adalimumab). The results of these trials were generally a statistically significant improvement from each of the TNF-alpha inhibitors. A Bayesian mixed treatment comparison (MTC) showed there was generally overlap in the 95 % credible intervals (CrIs) between the TNF-alpha inhibitors. Exceptions included a greater risk of discontinuation of treatment for golimumab than for etanercept (relative risk [RR] 4.30; 95 % CrI 1.01-18.50). The cost-effectiveness analysis (CEA) compared all of these TNF-alpha inhibitors. Relative effectiveness was informed only by RR of response (proportion achieving at least a 50 % improvement in Bath AS Disease Activity Index [BASDAI] score; BASDAI50) from the MTC. In the base-case analysis, the incremental cost-effectiveness ratio (ICER) of golimumab versus conventional care was pound26,597 and adalimumab and etanercept were extendedly dominated by golimumab. The manufacturer concluded that golimumab is a cost-effective treatment option. Generally, the ERG agreed with the MTC analyses. The main problem was that the MS used data from one trial, which included a period of cross-over. The ERG found some problems with the CEA model, mainly that it did not allow for comparison of TNF-alpha inhibitor sequences and did not use MTC estimates for treatment discontinuation or adverse events (AEs). The ERG could not correct the sequencing problem, but re-ran the CEA with discontinuations and AEs estimated from the MTC and using the correct trial data. The results of the ERG analysis were that golimumab was extendedly dominated by etanercept, and the preferred treatment was either conventional treatment or etanercept, depending on the ICER threshold. Uncertainty was also substantial. NICE issued guidance (technology appraisal [TA] 233), which recommended golimumab according to the indications described in TA143 for etanercept and adalimumab, i.e. as first-line therapy among the TNF-alpha inhibitors unless patients are intolerant to one or both alternatives. Given the factors cited by NICE for their decision, the ERG recommends that there should be greater clarity in the NICE methods guidance on handling uncertainty in CEAs as well as the incorporation of benefit from process of care.",2013-01-19312,23580355,Pharmacoeconomics,Nigel Armstrong,2013,31 / 5,415-25,Yes,23580355,"Nigel Armstrong; Manuela Joore; Thea van Asselt; Kate Misso; Nathan Manning; Florian Tomini; Jos Kleijnen; Rob Riemsma; Golimumab for the treatment of ankylosing spondylitis: a NICE single technology appraisal, Pharmacoeconomics, ; 31(5):1179-2027; 415-25",QALY,United Kingdom,Not Stated,Not Stated,Etanercept vs. adalimumab,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,Not Stated,Not Stated,17931.04,United Kingdom,2011,33098.59
12210,Golimumab for the treatment of ankylosing spondylitis: a NICE single technology appraisal,"As part of the National Institute for Health and Clinical Excellence (NICE) single technology appraisal (STA) process, the Evidence Review Group (ERG) produced a report to comment on the clinical and cost effectiveness of golimumab (Simponi((R)), Merck Sharp & Dohme) for the treatment of ankylosing spondylitis (AS) relative to other comparators as presented in the manufacturer''s submission (MS) to NICE. The population was those with active disease who had not responded to conventional therapy. The specified comparators were conventional care and two other tumour necrosis factor alpha (TNF-alpha) inhibitors (adalimumab and etanercept). Outcomes to be considered were disease activity, functional capacity, disease progression, adverse effects of treatment and health-related quality of life (HR-QOL). There were no head-to-head trials comparing TNF-alpha inhibitors. The submission included one trial of golimumab versus placebo (the GO-RAISE trial) and additionally seven placebo-controlled randomized controlled trials (RCTs) of other TNF-alpha inhibitor agents (five with etanercept, and two with adalimumab). The results of these trials were generally a statistically significant improvement from each of the TNF-alpha inhibitors. A Bayesian mixed treatment comparison (MTC) showed there was generally overlap in the 95 % credible intervals (CrIs) between the TNF-alpha inhibitors. Exceptions included a greater risk of discontinuation of treatment for golimumab than for etanercept (relative risk [RR] 4.30; 95 % CrI 1.01-18.50). The cost-effectiveness analysis (CEA) compared all of these TNF-alpha inhibitors. Relative effectiveness was informed only by RR of response (proportion achieving at least a 50 % improvement in Bath AS Disease Activity Index [BASDAI] score; BASDAI50) from the MTC. In the base-case analysis, the incremental cost-effectiveness ratio (ICER) of golimumab versus conventional care was pound26,597 and adalimumab and etanercept were extendedly dominated by golimumab. The manufacturer concluded that golimumab is a cost-effective treatment option. Generally, the ERG agreed with the MTC analyses. The main problem was that the MS used data from one trial, which included a period of cross-over. The ERG found some problems with the CEA model, mainly that it did not allow for comparison of TNF-alpha inhibitor sequences and did not use MTC estimates for treatment discontinuation or adverse events (AEs). The ERG could not correct the sequencing problem, but re-ran the CEA with discontinuations and AEs estimated from the MTC and using the correct trial data. The results of the ERG analysis were that golimumab was extendedly dominated by etanercept, and the preferred treatment was either conventional treatment or etanercept, depending on the ICER threshold. Uncertainty was also substantial. NICE issued guidance (technology appraisal [TA] 233), which recommended golimumab according to the indications described in TA143 for etanercept and adalimumab, i.e. as first-line therapy among the TNF-alpha inhibitors unless patients are intolerant to one or both alternatives. Given the factors cited by NICE for their decision, the ERG recommends that there should be greater clarity in the NICE methods guidance on handling uncertainty in CEAs as well as the incorporation of benefit from process of care.",2013-01-19312,23580355,Pharmacoeconomics,Nigel Armstrong,2013,31 / 5,415-25,Yes,23580355,"Nigel Armstrong; Manuela Joore; Thea van Asselt; Kate Misso; Nathan Manning; Florian Tomini; Jos Kleijnen; Rob Riemsma; Golimumab for the treatment of ankylosing spondylitis: a NICE single technology appraisal, Pharmacoeconomics, ; 31(5):1179-2027; 415-25",QALY,United Kingdom,Not Stated,Not Stated,Adalimumab vs. golimumab,Not Stated,Not Stated,Not Stated,"Female, Male",Full,Lifetime,Not Stated,Not Stated,26377.33,United Kingdom,2011,48689.45
12211,Bivalirudin for the treatment of ST-segment elevation myocardial infarction: a NICE single technology appraisal,"The National Institute for Health and Clinical Excellence (NICE) invited the manufacturer (The Medicines Company) of bivalirudin to submit evidence for its clinical and cost effectiveness within its licensed indication for the treatment of adults with ST-segment elevation myocardial infarction (STEMI) intended for primary percutaneous coronary intervention (PPCI), as part of NICE''s single technology appraisal (STA) process. The School of Health and Related Research (ScHARR) at the University of Sheffield was commissioned to act as the Evidence Review Group (ERG), which produced a review of the evidence within the manufacturer''s submission to NICE. This article describes the manufacturer''s submission, the ERG review and NICE''s subsequent decisions. The main evidence was derived from one randomized controlled trial (RCT) of STEMI patients intended for PPCI, comparing bivalirudin with unfractionated heparin plus glycoprotein IIb/IIIa inhibitors (GPIs). Bivalirudin was associated with a significant reduction in cardiac mortality at 30 days (p = 0.03) and at 1-year follow-up (p = 0.005), and a significant reduction in major bleeding at 30 days (p < 0.001) and 1 year (p < 0.0001), compared with heparin plus GPI. Stent thrombosis up to 24 hours following PPCI was significantly (p < 0.001) more common with bivalirudin. However, there was no significant treatment effect for stent thrombosis from 1 to 30 days (p = 0.28), or at 1-year follow-up (p = 0.53). There were no significant treatment group differences at 30 days and at 1 year in stroke (p = 0.68 and p = 0.99, respectively), in myocardial infarction [MI] (p = 0.90 and p = 0.22, respectively), or in the need for the revascularization of the target vessel for ischaemia (p = 0.18 and p = 0.12, respectively). There were two decision-analytic models: the base-case scenario used 1-year follow-up data from the RCT; and a sensitivity analysis used 3-year follow-up data. Resource use was primarily drawn from this RCT. Health-related quality-of-life (HR-QOL) estimates were drawn from a UK cohort study. Both models evaluated the incremental costs and outcomes of bivalirudin compared with heparin plus GPI for patients with STEMI intended for PPCI. The analysis adopted a UK NHS perspective over a lifetime horizon. Unit costs were based on year 2009-2010 prices. The model adopted a decision-tree structure to reflect initial events for the initial period (stroke, repeat MI, minor/major bleeding events, repeat revascularization and death) and a two-state Markov component to simulate longer-term survival. The economic analysis suggested that bivalirudin is expected to dominate the heparin plus GPI strategy. This finding was consistent across the probabilistic sensitivity analysis and the vast majority of deterministic sensitivity analyses undertaken. Three exceptions to this finding were observed for the following sensitivity analyses: (1) the exclusive use of eptifibatide as the GPI (incremental cost-effectiveness ratio [ICER] = pound1,764); (2) the combination of 100 % eptifibatide use, 100 % radial arterial access and no differential length between strategies for initial hospital stay (ICER = pound4,106); and (3) a longer length of ward stay (increase of 0.33 days) for the initial hospitalization (ICER = pound415). The Appraisal Committee (AC) gave a positive recommendation for bivalirudin for the treatment of adults with STEMI undergoing PPCI.",2013-01-19323,23512147,Pharmacoeconomics,E L Simpson,2013,31 / 4,269-75,Yes,23512147,"E L Simpson; P Fitzgerald; P Evans; P Tappenden; N Kalita; J P D Reckless; A Bakhai; Bivalirudin for the treatment of ST-segment elevation myocardial infarction: a NICE single technology appraisal, Pharmacoeconomics, ; 31(4):1179-2027; 269-75",QALY,United Kingdom,Not Stated,Not Stated,Bivalirudin vs. Standard/Usual Care- unfractionated heparin plus glycoprotein lib/llla inhibitors,Not Stated,Not Stated,Not Stated,Not Stated,Full,Lifetime,Not Stated,Not Stated,Not Stated,United Kingdom,2009,Not Stated
12212,The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment,"The outlook for transplant-ineligible multiple myeloma patients has improved enormously over recent years with the incorporation of new agents into standard regimens. Novel regimens combine melphalan and prednisone (MP) with bortezomib (VMP), with thalidomide (MPT), and with lenalidomide with (MPR-R) and without (MPR) lenalidomide maintenance. The efficacy, safety, and cost-effectiveness of these regimens have not yet been compared; therefore, we conducted a pharmacoeconomic analysis using data from randomized controlled trials versus MP. Using a Markov model developed from a U.S. payer''s perspective, we compared VMP with MPT and MPR-R over a lifetime horizon. MPT and MPR-R were chosen because, like VMP, they are superior to MP in response and outcomes. Data from the Velcade as Initial Standard Therapy in Multiple Myeloma (VISTA; VMP), Intergroupe Francophone du Myelome (IFM) 99-06 (MPT), and MM-015 (MPR-R) trials were used. The IFM 99-06 study was selected because of the superior activity in this study compared with other MPT studies. Using patient-level (VMP) and published (MPT, MPR-R) data, we estimated the health-state transition and adverse event probabilities for each regimen, related costs, and state-specific utility estimates. Costs (in 2010 U.S. dollars) and health outcomes were discounted at 3%. Discounted lifetime direct medical costs were lowest with VMP at $119,102. MPT cost $142,452 whereas MPR-R cost $248,358. Incremental cost-effectiveness ratio calculations projected that VMP would confer cost savings and better health outcomes relative to MPT and MPR-R. We conclude that VMP is highly likely to be cost-effective compared with MP, MPT, and MPR-R.",2013-01-19341,23299777,Oncologist,Louis P Jr Garrison,2013,18 / 1,27-36,No,23299777,"Louis P Jr Garrison; Si-Tien Wang; Hui Huang; Abbie Ba-Mancini; Hongliang Shi; Kristina Chen; Caroline Korves; Ravinder Dhawan; Andrew Cakana; Helgi van de Velde; Deyanira Corzo; Mei Sheng Duh; The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment, Oncologist, 2013; 18(1):1083-7159; 27-36",QALY,United States of America,Not Stated,Not Stated,"Bortezomib, melphalan and prednisone vs. melphalan and prednisone",Not Stated,Not Stated,19 Years,"Female, Male",Full,Lifetime,3.00,3.00,59076,United States,2010,70117.39
12213,The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment,"The outlook for transplant-ineligible multiple myeloma patients has improved enormously over recent years with the incorporation of new agents into standard regimens. Novel regimens combine melphalan and prednisone (MP) with bortezomib (VMP), with thalidomide (MPT), and with lenalidomide with (MPR-R) and without (MPR) lenalidomide maintenance. The efficacy, safety, and cost-effectiveness of these regimens have not yet been compared; therefore, we conducted a pharmacoeconomic analysis using data from randomized controlled trials versus MP. Using a Markov model developed from a U.S. payer''s perspective, we compared VMP with MPT and MPR-R over a lifetime horizon. MPT and MPR-R were chosen because, like VMP, they are superior to MP in response and outcomes. Data from the Velcade as Initial Standard Therapy in Multiple Myeloma (VISTA; VMP), Intergroupe Francophone du Myelome (IFM) 99-06 (MPT), and MM-015 (MPR-R) trials were used. The IFM 99-06 study was selected because of the superior activity in this study compared with other MPT studies. Using patient-level (VMP) and published (MPT, MPR-R) data, we estimated the health-state transition and adverse event probabilities for each regimen, related costs, and state-specific utility estimates. Costs (in 2010 U.S. dollars) and health outcomes were discounted at 3%. Discounted lifetime direct medical costs were lowest with VMP at $119,102. MPT cost $142,452 whereas MPR-R cost $248,358. Incremental cost-effectiveness ratio calculations projected that VMP would confer cost savings and better health outcomes relative to MPT and MPR-R. We conclude that VMP is highly likely to be cost-effective compared with MP, MPT, and MPR-R.",2013-01-19341,23299777,Oncologist,Louis P Jr Garrison,2013,18 / 1,27-36,No,23299777,"Louis P Jr Garrison; Si-Tien Wang; Hui Huang; Abbie Ba-Mancini; Hongliang Shi; Kristina Chen; Caroline Korves; Ravinder Dhawan; Andrew Cakana; Helgi van de Velde; Deyanira Corzo; Mei Sheng Duh; The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment, Oncologist, 2013; 18(1):1083-7159; 27-36",QALY,United States of America,Not Stated,Not Stated,Bortezomib and prednisone with lenalidomide maintenance vs. bortezomib and melphalan and prednisone,Not Stated,Not Stated,19 Years,"Female, Male",Full,Lifetime,3.00,3.00,-228367.5,United States,2010,-271049.74
12214,The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment,"The outlook for transplant-ineligible multiple myeloma patients has improved enormously over recent years with the incorporation of new agents into standard regimens. Novel regimens combine melphalan and prednisone (MP) with bortezomib (VMP), with thalidomide (MPT), and with lenalidomide with (MPR-R) and without (MPR) lenalidomide maintenance. The efficacy, safety, and cost-effectiveness of these regimens have not yet been compared; therefore, we conducted a pharmacoeconomic analysis using data from randomized controlled trials versus MP. Using a Markov model developed from a U.S. payer''s perspective, we compared VMP with MPT and MPR-R over a lifetime horizon. MPT and MPR-R were chosen because, like VMP, they are superior to MP in response and outcomes. Data from the Velcade as Initial Standard Therapy in Multiple Myeloma (VISTA; VMP), Intergroupe Francophone du Myelome (IFM) 99-06 (MPT), and MM-015 (MPR-R) trials were used. The IFM 99-06 study was selected because of the superior activity in this study compared with other MPT studies. Using patient-level (VMP) and published (MPT, MPR-R) data, we estimated the health-state transition and adverse event probabilities for each regimen, related costs, and state-specific utility estimates. Costs (in 2010 U.S. dollars) and health outcomes were discounted at 3%. Discounted lifetime direct medical costs were lowest with VMP at $119,102. MPT cost $142,452 whereas MPR-R cost $248,358. Incremental cost-effectiveness ratio calculations projected that VMP would confer cost savings and better health outcomes relative to MPT and MPR-R. We conclude that VMP is highly likely to be cost-effective compared with MP, MPT, and MPR-R.",2013-01-19341,23299777,Oncologist,Louis P Jr Garrison,2013,18 / 1,27-36,No,23299777,"Louis P Jr Garrison; Si-Tien Wang; Hui Huang; Abbie Ba-Mancini; Hongliang Shi; Kristina Chen; Caroline Korves; Ravinder Dhawan; Andrew Cakana; Helgi van de Velde; Deyanira Corzo; Mei Sheng Duh; The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment, Oncologist, 2013; 18(1):1083-7159; 27-36",QALY,United States of America,Not Stated,Not Stated,"Bortezomib, prednisone and thalidomide vs. bortezomib and melphalan and prednisone",Not Stated,Not Stated,19 Years,"Female, Male",Full,Lifetime,3.00,3.00,-543023.25,United States,2010,-644515.13
12215,Cost-utility analysis modeling at 2-year follow-up for cervical disc arthroplasty versus anterior cervical discectomy and fusion: A single-center contribution to the randomized controlled trial,"BACKGROUND: Patients with cervical disc herniations resulting in radiculopathy or myelopathy from single level disease have traditionally been treated with Anterior Cervical Discectomy and Fusion (ACDF), yet Cervical Disc Arthroplasty (CDA) is a new alternative. Expert suggestion of reduced adjacent segment degeneration is a promising future result of CDA. A cost-utility analysis of these procedures with long-term follow-up has not been previously reported. METHODS: We reviewed single institution prospective data from a randomized trial comparing single-level ACDF and CDA in cervical disc disease. Both Medicare reimbursement schedules and actual hospital cost data for peri-operative care were separately reviewed and analyzed to estimate the cost of treatment of each patient. QALYs were calculated at 1 and 2 years based on NDI and SF-36 outcome scores, and incremental cost effectiveness ratio (ICER) analysis was performed to determine relative cost-effectiveness. RESULTS: Patients of both groups showed improvement in NDI and SF-36 outcome scores. Medicare reimbursement rates to the hospital were $11,747 and $10,015 for ACDF and CDA, respectively; these figures rose to $16,162 and $13,171 when including physician and anesthesiologist reimbursement. The estimated actual cost to the hospital of ACDF averaged $16,108, while CDA averaged $16,004 (p = 0.97); when including estimated physicians fees, total hospital costs came to $19,811 and $18,440, respectively. The cost/QALY analyses therefore varied widely with these discrepancies in cost values. The ICERs of ACDF vs CDA with Medicare reimbursements were $18,593 (NDI) and $19,940 (SF-36), while ICERs based on actual total hospital cost were $13,710 (NDI) and $9,140 (SF-36). CONCLUSIONS: We confirm the efficacy of ACDF and CDA in the treatment of cervical disc disease, as our results suggest similar clinical outcomes at one and two year follow-up. The ICER suggests that the non-significant added benefit via ACDF comes at a reasonable cost, whether we use actual hospital costs or Medicare reimbursement values, though the actual ICER values vary widely depending upon the CUA modality used. Long term follow-up may illustrate a different profile for CDA due to reduced cost and greater long-term utility scores. It is crucial to note that financial modeling plays an important role in how economic treatment dominance is portrayed.",2013-01-19342,25694905,Aust N Z J Public Health,Daniel Warren,2013,7 /,e58-66,No,25694905,"Daniel Warren; Tate Andres; Christian Hoelscher; Pedro Ricart-Hoffiz; John Bendo; Jeffrey Goldstein; Cost-utility analysis modeling at 2-year follow-up for cervical disc arthroplasty versus anterior cervical discectomy and fusion: A single-center contribution to the randomized controlled trial, Aust N Z J Public Health, 2013; 7():1753-6405; e58-66",QALY,United States of America,Not Stated,Not Stated,Anterior Cervical Discectomy and Fusion vs. Cervical Disc Arthroplasty (CDA),Not Stated,Not Stated,19 Years,"Female, Male",Full,"2 Years, 1 year",Not Stated,Not Stated,29910,United States,2011,34413.94
12230,When is carotid angioplasty and stenting the cost-effective alternative for revascularization of symptomatic carotid stenosis? A Canadian health system perspective,"BACKGROUND AND PURPOSE: Carotid revascularization procedures can be complicated by stroke. Additional disability adds to the already high costs of the procedure. To weigh the cost and benefit, we estimated the cost-utility of carotid angioplasty and stenting compared with carotid endarterectomy among patients with symptomatic carotid stenosis, with special emphasis on scenario analyses that would yield carotid angioplasty and stenting as the cost-effective alternative relative to carotid endarterectomy. MATERIALS AND METHODS: A cost-utility analysis from the perspective of the health system payer was performed by using a Markov analytic model. Clinical estimates were based on a meta-analysis. The procedural costs were derived from a microcosting data base. The costs for hospitalization and rehabilitation of patients with stroke were based on a Canadian multicenter study. Utilities were based on a randomized controlled trial. RESULTS: In the base case analysis, carotid angioplasty and stenting were more expensive (incremental cost of $6107) and had a lower utility (-0.12 quality-adjusted life years) than carotid endarterectomy. The results are sensitive to changes in the risk of clinical events and the relative risk of death and stroke. Carotid angioplasty and stenting were more economically attractive among high-risk surgical patients. For carotid angioplasty and stenting to become the preferred option, their costs would need to fall from more than $7300 to $4350 or less and the risks of the periprocedural and annual minor strokes would have to be equivalent to that of carotid endarterectomy. CONCLUSIONS: In the base case analysis, carotid angioplasty and stenting were associated with higher costs and lower utility compared with carotid endarterectomy for patients with symptomatic carotid stenosis. Carotid angioplasty and stenting were cost-effective for patients with high surgical risk.",2014-01-14159,23928136,AJNR Am J Neuroradiol,M A Almekhlafi,2014,35 / 2,327-32,No,23928136,"M A Almekhlafi; M D Hill; S Wiebe; M Goyal; D Yavin; J H Wong; F M Clement; When is carotid angioplasty and stenting the cost-effective alternative for revascularization of symptomatic carotid stenosis? A Canadian health system perspective, AJNR Am J Neuroradiol, ; 35(2):0195-6108; 327-32",QALY,Canada,Not Stated,Not Stated,Carotid angioplasty and stent placement vs. Carotid endarterectomy,Not Stated,Not Stated,19 Years,Not Stated,Full,Lifetime,5.00,5.00,-50891.67,Canada,2012,-57381.09
12231,Is testosterone replacement therapy in males with hypogonadism cost-effective? An analysis in Sweden,"INTRODUCTION: Testosterone replacement therapy (TRT) has been recommended for the treatment of primary and secondary hypogonadism. However, long-term implications of TRT have not been investigated extensively. AIM: The aim of this analysis was to evaluate health outcomes and costs associated with life-long TRT in patients suffering from Klinefelter syndrome and late-onset hypogonadism (LOH). METHODS: A Markov model was developed to assess cost-effectiveness of testosterone undecanoate (TU) depot injection treatment compared with no treatment. Health outcomes and associated costs were modeled in monthly cycles per patient individually along a lifetime horizon. Modeled health outcomes included development of type 2 diabetes, depression, cardiovascular and cerebrovascular complications, and fractures. Analysis was performed for the Swedish health-care setting from health-care payer''s and societal perspective. One-way sensitivity analyses evaluated the robustness of results. MAIN OUTCOME MEASURES: The main outcome measures were quality-adjusted life-years (QALYs) and total cost in TU depot injection treatment and no treatment cohorts. In addition, outcomes were also expressed as incremental cost per QALY gained for TU depot injection therapy compared with no treatment (incremental cost-effectiveness ratio [ICER]). RESULTS: TU depot injection compared to no-treatment yielded a gain of 1.67 QALYs at an incremental cost of 28,176 EUR (37,192 USD) in the Klinefelter population. The ICER was 16,884 EUR (22,287 USD) per QALY gained. Outcomes in LOH population estimated benefits of TRT at 19,719 EUR (26,029 USD) per QALY gained. Results showed to be considerably robust when tested in sensitivity analyses. Variation of relative risk to develop type 2 diabetes had the highest impact on long-term outcomes in both patient groups. CONCLUSION: This analysis suggests that lifelong TU depot injection therapy of patients with hypogonadism is a cost-effective treatment in Sweden. Hence, it can support clinicians in decision making when considering appropriate treatment strategies for patients with testosterone deficiency.",2014-01-14174,23937088,J Sex Med,Stefan Arver,2014,11 / 1,262-72,No,23937088,"Stefan Arver; Ba Luong; Anina Fraschke; Ola Ghatnekar; Sanja Stanisic; Dmitry Gultyev; Elvira Muller; Is testosterone replacement therapy in males with hypogonadism cost-effective? An analysis in Sweden, J Sex Med, ; 11(1):1743-6109; 262-72",QALY,Sweden,Not Stated,Not Stated,Testosterone Undecanoate depot injection vs. No treatment,Not Stated,Not Stated,Not Stated,Male,Full,Lifetime,3.00,3.00,16884,Euro,2009,28384.26
12232,Is testosterone replacement therapy in males with hypogonadism cost-effective? An analysis in Sweden,"INTRODUCTION: Testosterone replacement therapy (TRT) has been recommended for the treatment of primary and secondary hypogonadism. However, long-term implications of TRT have not been investigated extensively. AIM: The aim of this analysis was to evaluate health outcomes and costs associated with life-long TRT in patients suffering from Klinefelter syndrome and late-onset hypogonadism (LOH). METHODS: A Markov model was developed to assess cost-effectiveness of testosterone undecanoate (TU) depot injection treatment compared with no treatment. Health outcomes and associated costs were modeled in monthly cycles per patient individually along a lifetime horizon. Modeled health outcomes included development of type 2 diabetes, depression, cardiovascular and cerebrovascular complications, and fractures. Analysis was performed for the Swedish health-care setting from health-care payer''s and societal perspective. One-way sensitivity analyses evaluated the robustness of results. MAIN OUTCOME MEASURES: The main outcome measures were quality-adjusted life-years (QALYs) and total cost in TU depot injection treatment and no treatment cohorts. In addition, outcomes were also expressed as incremental cost per QALY gained for TU depot injection therapy compared with no treatment (incremental cost-effectiveness ratio [ICER]). RESULTS: TU depot injection compared to no-treatment yielded a gain of 1.67 QALYs at an incremental cost of 28,176 EUR (37,192 USD) in the Klinefelter population. The ICER was 16,884 EUR (22,287 USD) per QALY gained. Outcomes in LOH population estimated benefits of TRT at 19,719 EUR (26,029 USD) per QALY gained. Results showed to be considerably robust when tested in sensitivity analyses. Variation of relative risk to develop type 2 diabetes had the highest impact on long-term outcomes in both patient groups. CONCLUSION: This analysis suggests that lifelong TU depot injection therapy of patients with hypogonadism is a cost-effective treatment in Sweden. Hence, it can support clinicians in decision making when considering appropriate treatment strategies for patients with testosterone deficiency.",2014-01-14174,23937088,J Sex Med,Stefan Arver,2014,11 / 1,262-72,No,23937088,"Stefan Arver; Ba Luong; Anina Fraschke; Ola Ghatnekar; Sanja Stanisic; Dmitry Gultyev; Elvira Muller; Is testosterone replacement therapy in males with hypogonadism cost-effective? An analysis in Sweden, J Sex Med, ; 11(1):1743-6109; 262-72",QALY,Sweden,Not Stated,Not Stated,Testosterone Undecanoate depot injection vs. None,Not Stated,Not Stated,19 Years,Male,Full,Lifetime,3.00,3.00,19720,Euro,2009,33151.95
12233,Modelling the cost-effectiveness of preventing major depression in general practice patients,"BACKGROUND: The prevention of depression is a key public health policy priority. PredictD is the first risk algorithm for the prediction of the onset of major depression. Our aim in this study was to model the cost-effectiveness of PredictD in depression prevention in general practice (GP). METHOD: A decision analytical model was developed to determine the cost-effectiveness of two approaches, each of which was compared to treatment as usual (TAU) over 12 months: (1) the PredictD risk algorithm plus a low-intensity depression prevention programme; and (2) a universal prevention programme in which there was no initial identification of those at risk. The model simulates the incidence of depression and disease progression over 12 months and calculates the net monetary benefit (NMB) from the National Health Service (NHS) perspective. RESULTS: Providing patients with PredictD and a depression prevention programme prevented 15 (17%) cases of depression in a cohort of 1000 patients over 12 months and had the highest probability of being the optimal choice at a willingness to pay (WTP) of pound20,000 for a quality-adjusted life year (QALY). Universal prevention was strongly dominated by PredictD plus a depression prevention programme in that universal prevention resulted in less QALYs than PredictD plus prevention for a greater cost. CONCLUSIONS: Using PredictD to identify primary-care patients at high risk of depression and providing them with a low-intensity prevention programme is potentially cost-effective at a WTP of pound20,000 per QALY.",2014-01-14194,23947797,Psychol Med,R M Hunter,2014,44 / 7,1381-90,No,23947797,"R M Hunter; I Nazareth; S Morris; M King; Modelling the cost-effectiveness of preventing major depression in general practice patients, Psychol Med, ; 44(7):1469-8978; 1381-90",QALY,United Kingdom,Not Stated,Not Stated,Risk algorithm (PredictD) plus prevention programme vs. Standard/Usual Care- Treatment as usual (TAU),Not Stated,Not Stated,19 Years,"Female, Male",Full,12 Months,Not Stated,Not Stated,9607.67,United Kingdom,2010,17604.34
12234,Modelling the cost-effectiveness of preventing major depression in general practice patients,"BACKGROUND: The prevention of depression is a key public health policy priority. PredictD is the first risk algorithm for the prediction of the onset of major depression. Our aim in this study was to model the cost-effectiveness of PredictD in depression prevention in general practice (GP). METHOD: A decision analytical model was developed to determine the cost-effectiveness of two approaches, each of which was compared to treatment as usual (TAU) over 12 months: (1) the PredictD risk algorithm plus a low-intensity depression prevention programme; and (2) a universal prevention programme in which there was no initial identification of those at risk. The model simulates the incidence of depression and disease progression over 12 months and calculates the net monetary benefit (NMB) from the National Health Service (NHS) perspective. RESULTS: Providing patients with PredictD and a depression prevention programme prevented 15 (17%) cases of depression in a cohort of 1000 patients over 12 months and had the highest probability of being the optimal choice at a willingness to pay (WTP) of pound20,000 for a quality-adjusted life year (QALY). Universal prevention was strongly dominated by PredictD plus a depression prevention programme in that universal prevention resulted in less QALYs than PredictD plus prevention for a greater cost. CONCLUSIONS: Using PredictD to identify primary-care patients at high risk of depression and providing them with a low-intensity prevention programme is potentially cost-effective at a WTP of pound20,000 per QALY.",2014-01-14194,23947797,Psychol Med,R M Hunter,2014,44 / 7,1381-90,No,23947797,"R M Hunter; I Nazareth; S Morris; M King; Modelling the cost-effectiveness of preventing major depression in general practice patients, Psychol Med, ; 44(7):1469-8978; 1381-90",QALY,United Kingdom,Not Stated,Not Stated,Universal Screening for Major Depression vs. Standard/Usual Care- Treatment as usual (TAU),Not Stated,Not Stated,19 Years,"Female, Male",Full,12 Months,Not Stated,Not Stated,85536,United Kingdom,2010,156729.46
12235,Optimizing screening for tuberculosis and hepatitis B prior to starting tumor necrosis factor-alpha inhibitors in Crohn's disease,"BACKGROUND AND AIMS: Treatment with tumor necrosis factor-alpha (TNF-alpha) inhibitors in patients with Crohn''s disease (CD) is associated with potentially serious infections, including tuberculosis (TB) and hepatitis B virus (HBV). We assessed the cost-effectiveness of extensive TB screening and HBV screening prior to initiating TNF-alpha inhibitors in CD. METHODS: We constructed two Markov models: (1) comparing tuberculin skin test (TST) combined with chest X-ray (conventional TB screening) versus TST and chest X-ray followed by the interferon-gamma release assay (extensive TB screening) in diagnosing TB; and (2) HBV screening versus no HBV screening. Our base-case included an adult CD patient starting with infliximab treatment. Input parameters were extracted from the literature. Direct medical costs were assessed and discounted following a third-party payer perspective. The main outcome was the incremental cost-effectiveness ratio (ICER). Sensitivity and Monte Carlo analyses were performed over wide ranges of probability and cost estimates. RESULTS: At base-case, the ICERs of extensive screening and HBV screening were euro64,340 and euro75,760 respectively to gain one quality-adjusted life year. Sensitivity analyses concluded that extensive TB screening was a cost-effective strategy if the latent TB prevalence is more than 12 % or if the false positivity rate of TST is more than 20 %. HBV screening became cost-effective if HBV reactivation or HBV-related mortality is higher than 37 and 62 %, respectively. CONCLUSIONS: Extensive TB screening and HBV screening are not cost-effective compared with conventional TB screening and no HBV screening, respectively. However, when targeted at high-risk patient groups, these screening strategies are likely to become cost-effective.",2014-01-14208,23949640,Dig Dis Sci,Mike van der Have,2014,59 / 3,554-63,No,23949640,"Mike van der Have; Bas Oldenburg; Herma H Fidder; Tim D G Belderbos; Peter D Siersema; Martijn G H van Oijen; Optimizing screening for tuberculosis and hepatitis B prior to starting tumor necrosis factor-alpha inhibitors in Crohn's disease, Dig Dis Sci, ; 59(3):0163-2116; 554-63",QALY,Netherlands,Not Stated,Not Stated,Extensive Tuberculosis Screening: initial screening with tuberculin skin test and chest X-ray followed by an IGRA (Quantiferon-TB Gold In-Tube) vs. conventional TB screening - including tuberculin skin test and chest X-ray,Not Stated,60 Years,30 Years,"Female, Male",Full,5 Years,3.00,3.00,64340,Euro,2012,93261.35
12236,Optimizing screening for tuberculosis and hepatitis B prior to starting tumor necrosis factor-alpha inhibitors in Crohn's disease,"BACKGROUND AND AIMS: Treatment with tumor necrosis factor-alpha (TNF-alpha) inhibitors in patients with Crohn''s disease (CD) is associated with potentially serious infections, including tuberculosis (TB) and hepatitis B virus (HBV). We assessed the cost-effectiveness of extensive TB screening and HBV screening prior to initiating TNF-alpha inhibitors in CD. METHODS: We constructed two Markov models: (1) comparing tuberculin skin test (TST) combined with chest X-ray (conventional TB screening) versus TST and chest X-ray followed by the interferon-gamma release assay (extensive TB screening) in diagnosing TB; and (2) HBV screening versus no HBV screening. Our base-case included an adult CD patient starting with infliximab treatment. Input parameters were extracted from the literature. Direct medical costs were assessed and discounted following a third-party payer perspective. The main outcome was the incremental cost-effectiveness ratio (ICER). Sensitivity and Monte Carlo analyses were performed over wide ranges of probability and cost estimates. RESULTS: At base-case, the ICERs of extensive screening and HBV screening were euro64,340 and euro75,760 respectively to gain one quality-adjusted life year. Sensitivity analyses concluded that extensive TB screening was a cost-effective strategy if the latent TB prevalence is more than 12 % or if the false positivity rate of TST is more than 20 %. HBV screening became cost-effective if HBV reactivation or HBV-related mortality is higher than 37 and 62 %, respectively. CONCLUSIONS: Extensive TB screening and HBV screening are not cost-effective compared with conventional TB screening and no HBV screening, respectively. However, when targeted at high-risk patient groups, these screening strategies are likely to become cost-effective.",2014-01-14208,23949640,Dig Dis Sci,Mike van der Have,2014,59 / 3,554-63,No,23949640,"Mike van der Have; Bas Oldenburg; Herma H Fidder; Tim D G Belderbos; Peter D Siersema; Martijn G H van Oijen; Optimizing screening for tuberculosis and hepatitis B prior to starting tumor necrosis factor-alpha inhibitors in Crohn's disease, Dig Dis Sci, ; 59(3):0163-2116; 554-63",QALY,Netherlands,Not Stated,Not Stated,"Hepatitis B Virus Screening (HbSAg, HbCAb), prior to TNF-a therapy. vs. No Hepatitis B Virus Screening",Not Stated,60 Years,30 Years,"Female, Male",Full,5 Years,3.00,3.00,93457.94,Euro,2012,135468.05
12237,Cost-effectiveness of combining systematic identification and treatment of co-morbid major depression for people with chronic diseases: the example of cancer,"BACKGROUND: Co-morbid major depression occurs in approximately 10% of people suffering from a chronic medical condition such as cancer. Systematic integrated management that includes both identification and treatment has been advocated. However, we lack information on the cost-effectiveness of this combined approach, as published evaluations have focused solely on the systematic (collaborative care) treatment stage. We therefore aimed to use the best available evidence to estimate the cost-effectiveness of systematic integrated management (both identification and treatment) compared with usual practice, for patients attending specialist cancer clinics. METHOD: We conducted a cost-effectiveness analysis using a decision analytic model structured to reflect both the identification and treatment processes. Evidence was taken from reviews of relevant clinical trials and from observational studies, together with data from a large depression screening service. Sensitivity and scenario analyses were undertaken to determine the effects of variations in depression incidence rates, time horizons and patient characteristics. RESULTS: Systematic integrated depression management generated more costs than usual practice, but also more quality-adjusted life years (QALYs). The incremental cost-effectiveness ratio (ICER) was pound11,765 per QALY. This finding was robust to tests of uncertainty and variation in key model parameters. CONCLUSIONS: Systematic integrated management of co-morbid major depression in cancer patients is likely to be cost-effective at widely accepted threshold values and may be a better way of generating QALYs for cancer patients than some existing medical and surgical treatments. It could usefully be applied to other chronic medical conditions.",2014-01-14221,23962484,Psychol Med,S Walker,2014,44 / 7,1451-60,No,23962484,"S Walker; J Walker; G Richardson; S Palmer; Q Wu; S Gilbody; P Martin; C Holm Hansen; A Sawhney; G Murray; M Sculpher; M Sharpe; Cost-effectiveness of combining systematic identification and treatment of co-morbid major depression for people with chronic diseases: the example of cancer, Psychol Med, ; 44(7):1469-8978; 1451-60",QALY,United Kingdom,Not Stated,Not Stated,Systematic identification and treatment of major depression vs. Standard/Usual Care- Usual practice: Identification of major depression by the patients primary care physician and Treatment of depression based on the PCPs clini- cal judgement,Not Stated,63 Years,63 Years,Female,Full,"5 Years, 10 and 20 years",3.50,3.50,11765.4,United Kingdom,2010,21558
12238,Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries,"OBJECTIVE: To assess the cost effectiveness for tuberculosis (TB) screening of high-risk human immunodeficiency virus (HIV) positive pregnant women by using interferon-gamma release assays (IGRAs) compared to the tuberculin skin test (TST) in low TB incidence countries. METHODS: We constructed Markov models using a public health payer perspective. The target population was a hypothetical cohort of 20 year-olds HIV positive pregnant women until age 50 years in three most common screening situations; close contacts, immigrants from high burden countries and occasional screenings. BCG vaccination status was considered. Five strategies; TST, QuantiFERON(R)-TB Gold In-Tube (QFT), T-SPOT(R). TB (T-SPOT), TST followed by QFT and TST followed by T-SPOT were modeled. The main outcome measure of effectiveness was quality-adjusted life-years (QALYs) gained. The incremental cost effectiveness ratio (ICER) of each screening arm was applied and compared. RESULTS: In the base case analyses of close contacts, T-SPOT yielded the greatest benefits at the lowest cost. In the base case analyses of immigrants and occasional screenings, TST followed by QFT yielded the greatest benefits at the lowest cost. CONCLUSIONS: Using an IGRA for TB screening of high-risk HIV positive pregnant women is recommended on the basis of the cost effectiveness in low TB incidence countries.",2014-01-14232,23973660,J Infect,Akiko Kowada,2014,68 / 1,32-42,No,23973660,"Akiko Kowada; Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries, J Infect, ; 68(1):1532-2742; 32-42",QALY,Japan,Not Stated,Not Stated,T-SPOT.Tuberculosis test vs. QuantiFERON - TB Gold In-Tube,pregnant women in close contacts. Non-BCG vaccinated cohort during pregnancy,50 Years,20 Years,Female,Full,30 Years,3.00,3.00,-83658.23,United States,2012,-94304.16
12239,Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries,"OBJECTIVE: To assess the cost effectiveness for tuberculosis (TB) screening of high-risk human immunodeficiency virus (HIV) positive pregnant women by using interferon-gamma release assays (IGRAs) compared to the tuberculin skin test (TST) in low TB incidence countries. METHODS: We constructed Markov models using a public health payer perspective. The target population was a hypothetical cohort of 20 year-olds HIV positive pregnant women until age 50 years in three most common screening situations; close contacts, immigrants from high burden countries and occasional screenings. BCG vaccination status was considered. Five strategies; TST, QuantiFERON(R)-TB Gold In-Tube (QFT), T-SPOT(R). TB (T-SPOT), TST followed by QFT and TST followed by T-SPOT were modeled. The main outcome measure of effectiveness was quality-adjusted life-years (QALYs) gained. The incremental cost effectiveness ratio (ICER) of each screening arm was applied and compared. RESULTS: In the base case analyses of close contacts, T-SPOT yielded the greatest benefits at the lowest cost. In the base case analyses of immigrants and occasional screenings, TST followed by QFT yielded the greatest benefits at the lowest cost. CONCLUSIONS: Using an IGRA for TB screening of high-risk HIV positive pregnant women is recommended on the basis of the cost effectiveness in low TB incidence countries.",2014-01-14232,23973660,J Infect,Akiko Kowada,2014,68 / 1,32-42,No,23973660,"Akiko Kowada; Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries, J Infect, ; 68(1):1532-2742; 32-42",QALY,Japan,Not Stated,Not Stated,T-SPOT.Tuberculosis test vs. Tuberculin Skin Test,pregnant women in close contacts. Non-BCG vaccinated cohort during pregnancy,50 Years,20 Years,Female,Full,30 Years,3.00,3.00,-84578.72,United States,2012,-95341.79
12240,Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries,"OBJECTIVE: To assess the cost effectiveness for tuberculosis (TB) screening of high-risk human immunodeficiency virus (HIV) positive pregnant women by using interferon-gamma release assays (IGRAs) compared to the tuberculin skin test (TST) in low TB incidence countries. METHODS: We constructed Markov models using a public health payer perspective. The target population was a hypothetical cohort of 20 year-olds HIV positive pregnant women until age 50 years in three most common screening situations; close contacts, immigrants from high burden countries and occasional screenings. BCG vaccination status was considered. Five strategies; TST, QuantiFERON(R)-TB Gold In-Tube (QFT), T-SPOT(R). TB (T-SPOT), TST followed by QFT and TST followed by T-SPOT were modeled. The main outcome measure of effectiveness was quality-adjusted life-years (QALYs) gained. The incremental cost effectiveness ratio (ICER) of each screening arm was applied and compared. RESULTS: In the base case analyses of close contacts, T-SPOT yielded the greatest benefits at the lowest cost. In the base case analyses of immigrants and occasional screenings, TST followed by QFT yielded the greatest benefits at the lowest cost. CONCLUSIONS: Using an IGRA for TB screening of high-risk HIV positive pregnant women is recommended on the basis of the cost effectiveness in low TB incidence countries.",2014-01-14232,23973660,J Infect,Akiko Kowada,2014,68 / 1,32-42,No,23973660,"Akiko Kowada; Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries, J Infect, ; 68(1):1532-2742; 32-42",QALY,Japan,Not Stated,Not Stated,T-SPOT.Tuberculosis test vs. Tuberculin Skin Test / T-SPOT.Tuberculosis,pregnant women in close contacts. Non-BCG vaccinated cohort during pregnancy,50 Years,20 Years,Female,Full,30 Years,3.00,3.00,-124484.44,United States,2012,-140325.71
12241,Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries,"OBJECTIVE: To assess the cost effectiveness for tuberculosis (TB) screening of high-risk human immunodeficiency virus (HIV) positive pregnant women by using interferon-gamma release assays (IGRAs) compared to the tuberculin skin test (TST) in low TB incidence countries. METHODS: We constructed Markov models using a public health payer perspective. The target population was a hypothetical cohort of 20 year-olds HIV positive pregnant women until age 50 years in three most common screening situations; close contacts, immigrants from high burden countries and occasional screenings. BCG vaccination status was considered. Five strategies; TST, QuantiFERON(R)-TB Gold In-Tube (QFT), T-SPOT(R). TB (T-SPOT), TST followed by QFT and TST followed by T-SPOT were modeled. The main outcome measure of effectiveness was quality-adjusted life-years (QALYs) gained. The incremental cost effectiveness ratio (ICER) of each screening arm was applied and compared. RESULTS: In the base case analyses of close contacts, T-SPOT yielded the greatest benefits at the lowest cost. In the base case analyses of immigrants and occasional screenings, TST followed by QFT yielded the greatest benefits at the lowest cost. CONCLUSIONS: Using an IGRA for TB screening of high-risk HIV positive pregnant women is recommended on the basis of the cost effectiveness in low TB incidence countries.",2014-01-14232,23973660,J Infect,Akiko Kowada,2014,68 / 1,32-42,No,23973660,"Akiko Kowada; Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries, J Infect, ; 68(1):1532-2742; 32-42",QALY,Japan,Not Stated,Not Stated,T-SPOT.Tuberculosis test vs. Tuberculin Skin Test / QuantiFERON - TB Gold In-Tube,pregnant women in close contacts. Non-BCG vaccinated cohort during pregnancy,50 Years,20 Years,Female,Full,30 Years,3.00,3.00,-123178.8,United States,2012,-138853.93
12242,Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries,"OBJECTIVE: To assess the cost effectiveness for tuberculosis (TB) screening of high-risk human immunodeficiency virus (HIV) positive pregnant women by using interferon-gamma release assays (IGRAs) compared to the tuberculin skin test (TST) in low TB incidence countries. METHODS: We constructed Markov models using a public health payer perspective. The target population was a hypothetical cohort of 20 year-olds HIV positive pregnant women until age 50 years in three most common screening situations; close contacts, immigrants from high burden countries and occasional screenings. BCG vaccination status was considered. Five strategies; TST, QuantiFERON(R)-TB Gold In-Tube (QFT), T-SPOT(R). TB (T-SPOT), TST followed by QFT and TST followed by T-SPOT were modeled. The main outcome measure of effectiveness was quality-adjusted life-years (QALYs) gained. The incremental cost effectiveness ratio (ICER) of each screening arm was applied and compared. RESULTS: In the base case analyses of close contacts, T-SPOT yielded the greatest benefits at the lowest cost. In the base case analyses of immigrants and occasional screenings, TST followed by QFT yielded the greatest benefits at the lowest cost. CONCLUSIONS: Using an IGRA for TB screening of high-risk HIV positive pregnant women is recommended on the basis of the cost effectiveness in low TB incidence countries.",2014-01-14232,23973660,J Infect,Akiko Kowada,2014,68 / 1,32-42,No,23973660,"Akiko Kowada; Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries, J Infect, ; 68(1):1532-2742; 32-42",QALY,Japan,Not Stated,Not Stated,T-SPOT.Tuberculosis test vs. QuantiFERON - TB Gold In-Tube,pregnant women in close contacts. BCG vaccinated cohort during pregnancy,50 Years,20 Years,Female,Full,30 Years,3.00,3.00,-83658.23,United States,2012,-94304.16
12243,Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries,"OBJECTIVE: To assess the cost effectiveness for tuberculosis (TB) screening of high-risk human immunodeficiency virus (HIV) positive pregnant women by using interferon-gamma release assays (IGRAs) compared to the tuberculin skin test (TST) in low TB incidence countries. METHODS: We constructed Markov models using a public health payer perspective. The target population was a hypothetical cohort of 20 year-olds HIV positive pregnant women until age 50 years in three most common screening situations; close contacts, immigrants from high burden countries and occasional screenings. BCG vaccination status was considered. Five strategies; TST, QuantiFERON(R)-TB Gold In-Tube (QFT), T-SPOT(R). TB (T-SPOT), TST followed by QFT and TST followed by T-SPOT were modeled. The main outcome measure of effectiveness was quality-adjusted life-years (QALYs) gained. The incremental cost effectiveness ratio (ICER) of each screening arm was applied and compared. RESULTS: In the base case analyses of close contacts, T-SPOT yielded the greatest benefits at the lowest cost. In the base case analyses of immigrants and occasional screenings, TST followed by QFT yielded the greatest benefits at the lowest cost. CONCLUSIONS: Using an IGRA for TB screening of high-risk HIV positive pregnant women is recommended on the basis of the cost effectiveness in low TB incidence countries.",2014-01-14232,23973660,J Infect,Akiko Kowada,2014,68 / 1,32-42,No,23973660,"Akiko Kowada; Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries, J Infect, ; 68(1):1532-2742; 32-42",QALY,Japan,Not Stated,Not Stated,T-SPOT.Tuberculosis test vs. Tuberculin Skin Test / T-SPOT.Tuberculosis,pregnant women in close contacts. BCG vaccinated cohort during pregnancy,50 Years,20 Years,Female,Full,30 Years,3.00,3.00,-113757.65,United States,2012,-128233.88
12244,Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries,"OBJECTIVE: To assess the cost effectiveness for tuberculosis (TB) screening of high-risk human immunodeficiency virus (HIV) positive pregnant women by using interferon-gamma release assays (IGRAs) compared to the tuberculin skin test (TST) in low TB incidence countries. METHODS: We constructed Markov models using a public health payer perspective. The target population was a hypothetical cohort of 20 year-olds HIV positive pregnant women until age 50 years in three most common screening situations; close contacts, immigrants from high burden countries and occasional screenings. BCG vaccination status was considered. Five strategies; TST, QuantiFERON(R)-TB Gold In-Tube (QFT), T-SPOT(R). TB (T-SPOT), TST followed by QFT and TST followed by T-SPOT were modeled. The main outcome measure of effectiveness was quality-adjusted life-years (QALYs) gained. The incremental cost effectiveness ratio (ICER) of each screening arm was applied and compared. RESULTS: In the base case analyses of close contacts, T-SPOT yielded the greatest benefits at the lowest cost. In the base case analyses of immigrants and occasional screenings, TST followed by QFT yielded the greatest benefits at the lowest cost. CONCLUSIONS: Using an IGRA for TB screening of high-risk HIV positive pregnant women is recommended on the basis of the cost effectiveness in low TB incidence countries.",2014-01-14232,23973660,J Infect,Akiko Kowada,2014,68 / 1,32-42,No,23973660,"Akiko Kowada; Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries, J Infect, ; 68(1):1532-2742; 32-42",QALY,Japan,Not Stated,Not Stated,T-SPOT.Tuberculosis test vs. Tuberculin Skin Test / QuantiFERON - TB Gold In-Tube,pregnant women in close contacts. BCG vaccinated cohort during pregnancy,50 Years,20 Years,Female,Full,30 Years,3.00,3.00,-118074.38,United States,2012,-133099.94
12245,Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries,"OBJECTIVE: To assess the cost effectiveness for tuberculosis (TB) screening of high-risk human immunodeficiency virus (HIV) positive pregnant women by using interferon-gamma release assays (IGRAs) compared to the tuberculin skin test (TST) in low TB incidence countries. METHODS: We constructed Markov models using a public health payer perspective. The target population was a hypothetical cohort of 20 year-olds HIV positive pregnant women until age 50 years in three most common screening situations; close contacts, immigrants from high burden countries and occasional screenings. BCG vaccination status was considered. Five strategies; TST, QuantiFERON(R)-TB Gold In-Tube (QFT), T-SPOT(R). TB (T-SPOT), TST followed by QFT and TST followed by T-SPOT were modeled. The main outcome measure of effectiveness was quality-adjusted life-years (QALYs) gained. The incremental cost effectiveness ratio (ICER) of each screening arm was applied and compared. RESULTS: In the base case analyses of close contacts, T-SPOT yielded the greatest benefits at the lowest cost. In the base case analyses of immigrants and occasional screenings, TST followed by QFT yielded the greatest benefits at the lowest cost. CONCLUSIONS: Using an IGRA for TB screening of high-risk HIV positive pregnant women is recommended on the basis of the cost effectiveness in low TB incidence countries.",2014-01-14232,23973660,J Infect,Akiko Kowada,2014,68 / 1,32-42,No,23973660,"Akiko Kowada; Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries, J Infect, ; 68(1):1532-2742; 32-42",QALY,Japan,Not Stated,Not Stated,T-SPOT.Tuberculosis test vs. Tuberculin Skin Test,pregnant women in close contacts. BCG vaccinated cohort during pregnancy,50 Years,20 Years,Female,Full,30 Years,3.00,3.00,-33558.62,United States,2012,-37829.12
12246,Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries,"OBJECTIVE: To assess the cost effectiveness for tuberculosis (TB) screening of high-risk human immunodeficiency virus (HIV) positive pregnant women by using interferon-gamma release assays (IGRAs) compared to the tuberculin skin test (TST) in low TB incidence countries. METHODS: We constructed Markov models using a public health payer perspective. The target population was a hypothetical cohort of 20 year-olds HIV positive pregnant women until age 50 years in three most common screening situations; close contacts, immigrants from high burden countries and occasional screenings. BCG vaccination status was considered. Five strategies; TST, QuantiFERON(R)-TB Gold In-Tube (QFT), T-SPOT(R). TB (T-SPOT), TST followed by QFT and TST followed by T-SPOT were modeled. The main outcome measure of effectiveness was quality-adjusted life-years (QALYs) gained. The incremental cost effectiveness ratio (ICER) of each screening arm was applied and compared. RESULTS: In the base case analyses of close contacts, T-SPOT yielded the greatest benefits at the lowest cost. In the base case analyses of immigrants and occasional screenings, TST followed by QFT yielded the greatest benefits at the lowest cost. CONCLUSIONS: Using an IGRA for TB screening of high-risk HIV positive pregnant women is recommended on the basis of the cost effectiveness in low TB incidence countries.",2014-01-14232,23973660,J Infect,Akiko Kowada,2014,68 / 1,32-42,No,23973660,"Akiko Kowada; Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries, J Infect, ; 68(1):1532-2742; 32-42",QALY,Japan,Not Stated,Not Stated,T-SPOT.Tuberculosis test vs. QuantiFERON - TB Gold In-Tube,pregnant women in close contacts. Non-BCG vaccinated cohort in postpartum period,50 Years,20 Years,Female,Full,30 Years,3.00,3.00,-1127.06,United States,2012,-1270.48
12247,Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries,"OBJECTIVE: To assess the cost effectiveness for tuberculosis (TB) screening of high-risk human immunodeficiency virus (HIV) positive pregnant women by using interferon-gamma release assays (IGRAs) compared to the tuberculin skin test (TST) in low TB incidence countries. METHODS: We constructed Markov models using a public health payer perspective. The target population was a hypothetical cohort of 20 year-olds HIV positive pregnant women until age 50 years in three most common screening situations; close contacts, immigrants from high burden countries and occasional screenings. BCG vaccination status was considered. Five strategies; TST, QuantiFERON(R)-TB Gold In-Tube (QFT), T-SPOT(R). TB (T-SPOT), TST followed by QFT and TST followed by T-SPOT were modeled. The main outcome measure of effectiveness was quality-adjusted life-years (QALYs) gained. The incremental cost effectiveness ratio (ICER) of each screening arm was applied and compared. RESULTS: In the base case analyses of close contacts, T-SPOT yielded the greatest benefits at the lowest cost. In the base case analyses of immigrants and occasional screenings, TST followed by QFT yielded the greatest benefits at the lowest cost. CONCLUSIONS: Using an IGRA for TB screening of high-risk HIV positive pregnant women is recommended on the basis of the cost effectiveness in low TB incidence countries.",2014-01-14232,23973660,J Infect,Akiko Kowada,2014,68 / 1,32-42,No,23973660,"Akiko Kowada; Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries, J Infect, ; 68(1):1532-2742; 32-42",QALY,Japan,Not Stated,Not Stated,T-SPOT.Tuberculosis test vs. Tuberculin Skin Test,pregnant women in close contacts. Non-BCG vaccinated cohort in postpartum period,50 Years,20 Years,Female,Full,30 Years,3.00,3.00,-5201.29,United States,2012,-5863.18
12248,Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries,"OBJECTIVE: To assess the cost effectiveness for tuberculosis (TB) screening of high-risk human immunodeficiency virus (HIV) positive pregnant women by using interferon-gamma release assays (IGRAs) compared to the tuberculin skin test (TST) in low TB incidence countries. METHODS: We constructed Markov models using a public health payer perspective. The target population was a hypothetical cohort of 20 year-olds HIV positive pregnant women until age 50 years in three most common screening situations; close contacts, immigrants from high burden countries and occasional screenings. BCG vaccination status was considered. Five strategies; TST, QuantiFERON(R)-TB Gold In-Tube (QFT), T-SPOT(R). TB (T-SPOT), TST followed by QFT and TST followed by T-SPOT were modeled. The main outcome measure of effectiveness was quality-adjusted life-years (QALYs) gained. The incremental cost effectiveness ratio (ICER) of each screening arm was applied and compared. RESULTS: In the base case analyses of close contacts, T-SPOT yielded the greatest benefits at the lowest cost. In the base case analyses of immigrants and occasional screenings, TST followed by QFT yielded the greatest benefits at the lowest cost. CONCLUSIONS: Using an IGRA for TB screening of high-risk HIV positive pregnant women is recommended on the basis of the cost effectiveness in low TB incidence countries.",2014-01-14232,23973660,J Infect,Akiko Kowada,2014,68 / 1,32-42,No,23973660,"Akiko Kowada; Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries, J Infect, ; 68(1):1532-2742; 32-42",QALY,Japan,Not Stated,Not Stated,T-SPOT.Tuberculosis test vs. Tuberculin Skin Test / T-SPOT.Tuberculosis test,pregnant women in close contacts. Non-BCG vaccinated cohort in postpartum period,50 Years,20 Years,Female,Full,30 Years,3.00,3.00,-4516.07,United States,2012,-5090.76
12249,Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries,"OBJECTIVE: To assess the cost effectiveness for tuberculosis (TB) screening of high-risk human immunodeficiency virus (HIV) positive pregnant women by using interferon-gamma release assays (IGRAs) compared to the tuberculin skin test (TST) in low TB incidence countries. METHODS: We constructed Markov models using a public health payer perspective. The target population was a hypothetical cohort of 20 year-olds HIV positive pregnant women until age 50 years in three most common screening situations; close contacts, immigrants from high burden countries and occasional screenings. BCG vaccination status was considered. Five strategies; TST, QuantiFERON(R)-TB Gold In-Tube (QFT), T-SPOT(R). TB (T-SPOT), TST followed by QFT and TST followed by T-SPOT were modeled. The main outcome measure of effectiveness was quality-adjusted life-years (QALYs) gained. The incremental cost effectiveness ratio (ICER) of each screening arm was applied and compared. RESULTS: In the base case analyses of close contacts, T-SPOT yielded the greatest benefits at the lowest cost. In the base case analyses of immigrants and occasional screenings, TST followed by QFT yielded the greatest benefits at the lowest cost. CONCLUSIONS: Using an IGRA for TB screening of high-risk HIV positive pregnant women is recommended on the basis of the cost effectiveness in low TB incidence countries.",2014-01-14232,23973660,J Infect,Akiko Kowada,2014,68 / 1,32-42,No,23973660,"Akiko Kowada; Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries, J Infect, ; 68(1):1532-2742; 32-42",QALY,Japan,Not Stated,Not Stated,T-SPOT.Tuberculosis test vs. Tuberculin Skin Test / QuantiFERON - TB Gold In-Tube,pregnant women in close contacts. Non-BCG vaccinated cohort in postpartum period,50 Years,20 Years,Female,Full,30 Years,3.00,3.00,-4517.93,United States,2012,-5092.86
12250,Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries,"OBJECTIVE: To assess the cost effectiveness for tuberculosis (TB) screening of high-risk human immunodeficiency virus (HIV) positive pregnant women by using interferon-gamma release assays (IGRAs) compared to the tuberculin skin test (TST) in low TB incidence countries. METHODS: We constructed Markov models using a public health payer perspective. The target population was a hypothetical cohort of 20 year-olds HIV positive pregnant women until age 50 years in three most common screening situations; close contacts, immigrants from high burden countries and occasional screenings. BCG vaccination status was considered. Five strategies; TST, QuantiFERON(R)-TB Gold In-Tube (QFT), T-SPOT(R). TB (T-SPOT), TST followed by QFT and TST followed by T-SPOT were modeled. The main outcome measure of effectiveness was quality-adjusted life-years (QALYs) gained. The incremental cost effectiveness ratio (ICER) of each screening arm was applied and compared. RESULTS: In the base case analyses of close contacts, T-SPOT yielded the greatest benefits at the lowest cost. In the base case analyses of immigrants and occasional screenings, TST followed by QFT yielded the greatest benefits at the lowest cost. CONCLUSIONS: Using an IGRA for TB screening of high-risk HIV positive pregnant women is recommended on the basis of the cost effectiveness in low TB incidence countries.",2014-01-14232,23973660,J Infect,Akiko Kowada,2014,68 / 1,32-42,No,23973660,"Akiko Kowada; Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries, J Infect, ; 68(1):1532-2742; 32-42",QALY,Japan,Not Stated,Not Stated,T-SPOT.Tuberculosis test vs. QuantiFERON - TB Gold In-Tube test,pregnant women in close contacts. BCG vaccinated cohort in postpartum period,50 Years,20 Years,Female,Full,30 Years,3.00,3.00,-1127.06,United States,2012,-1270.48
12251,Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries,"OBJECTIVE: To assess the cost effectiveness for tuberculosis (TB) screening of high-risk human immunodeficiency virus (HIV) positive pregnant women by using interferon-gamma release assays (IGRAs) compared to the tuberculin skin test (TST) in low TB incidence countries. METHODS: We constructed Markov models using a public health payer perspective. The target population was a hypothetical cohort of 20 year-olds HIV positive pregnant women until age 50 years in three most common screening situations; close contacts, immigrants from high burden countries and occasional screenings. BCG vaccination status was considered. Five strategies; TST, QuantiFERON(R)-TB Gold In-Tube (QFT), T-SPOT(R). TB (T-SPOT), TST followed by QFT and TST followed by T-SPOT were modeled. The main outcome measure of effectiveness was quality-adjusted life-years (QALYs) gained. The incremental cost effectiveness ratio (ICER) of each screening arm was applied and compared. RESULTS: In the base case analyses of close contacts, T-SPOT yielded the greatest benefits at the lowest cost. In the base case analyses of immigrants and occasional screenings, TST followed by QFT yielded the greatest benefits at the lowest cost. CONCLUSIONS: Using an IGRA for TB screening of high-risk HIV positive pregnant women is recommended on the basis of the cost effectiveness in low TB incidence countries.",2014-01-14232,23973660,J Infect,Akiko Kowada,2014,68 / 1,32-42,No,23973660,"Akiko Kowada; Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries, J Infect, ; 68(1):1532-2742; 32-42",QALY,Japan,Not Stated,Not Stated,T-SPOT.Tuberculosis test vs. Tuberculin Skin Test / T-SPOT.Tuberculosis test,pregnant women in close contacts. BCG vaccinated cohort during pregnancy,50 Years,20 Years,Female,Full,30 Years,3.00,3.00,-4921.75,United States,2012,-5548.07
12252,Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries,"OBJECTIVE: To assess the cost effectiveness for tuberculosis (TB) screening of high-risk human immunodeficiency virus (HIV) positive pregnant women by using interferon-gamma release assays (IGRAs) compared to the tuberculin skin test (TST) in low TB incidence countries. METHODS: We constructed Markov models using a public health payer perspective. The target population was a hypothetical cohort of 20 year-olds HIV positive pregnant women until age 50 years in three most common screening situations; close contacts, immigrants from high burden countries and occasional screenings. BCG vaccination status was considered. Five strategies; TST, QuantiFERON(R)-TB Gold In-Tube (QFT), T-SPOT(R). TB (T-SPOT), TST followed by QFT and TST followed by T-SPOT were modeled. The main outcome measure of effectiveness was quality-adjusted life-years (QALYs) gained. The incremental cost effectiveness ratio (ICER) of each screening arm was applied and compared. RESULTS: In the base case analyses of close contacts, T-SPOT yielded the greatest benefits at the lowest cost. In the base case analyses of immigrants and occasional screenings, TST followed by QFT yielded the greatest benefits at the lowest cost. CONCLUSIONS: Using an IGRA for TB screening of high-risk HIV positive pregnant women is recommended on the basis of the cost effectiveness in low TB incidence countries.",2014-01-14232,23973660,J Infect,Akiko Kowada,2014,68 / 1,32-42,No,23973660,"Akiko Kowada; Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries, J Infect, ; 68(1):1532-2742; 32-42",QALY,Japan,Not Stated,Not Stated,T-SPOT.Tuberculosis test vs. Tuberculin Skin Test / QuantiFERON - TB Gold In-Tube,pregnant women in close contacts. BCG vaccinated cohort in postpartum period,50 Years,20 Years,Female,Full,30 Years,3.00,3.00,-4802.15,United States,2012,-5413.25
12253,Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries,"OBJECTIVE: To assess the cost effectiveness for tuberculosis (TB) screening of high-risk human immunodeficiency virus (HIV) positive pregnant women by using interferon-gamma release assays (IGRAs) compared to the tuberculin skin test (TST) in low TB incidence countries. METHODS: We constructed Markov models using a public health payer perspective. The target population was a hypothetical cohort of 20 year-olds HIV positive pregnant women until age 50 years in three most common screening situations; close contacts, immigrants from high burden countries and occasional screenings. BCG vaccination status was considered. Five strategies; TST, QuantiFERON(R)-TB Gold In-Tube (QFT), T-SPOT(R). TB (T-SPOT), TST followed by QFT and TST followed by T-SPOT were modeled. The main outcome measure of effectiveness was quality-adjusted life-years (QALYs) gained. The incremental cost effectiveness ratio (ICER) of each screening arm was applied and compared. RESULTS: In the base case analyses of close contacts, T-SPOT yielded the greatest benefits at the lowest cost. In the base case analyses of immigrants and occasional screenings, TST followed by QFT yielded the greatest benefits at the lowest cost. CONCLUSIONS: Using an IGRA for TB screening of high-risk HIV positive pregnant women is recommended on the basis of the cost effectiveness in low TB incidence countries.",2014-01-14232,23973660,J Infect,Akiko Kowada,2014,68 / 1,32-42,No,23973660,"Akiko Kowada; Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries, J Infect, ; 68(1):1532-2742; 32-42",QALY,Japan,Not Stated,Not Stated,T-SPOT.Tuberculosis test vs. Tuberculin Skin Test,pregnant women in close contacts. BCG vaccinated cohort in postpartum period,50 Years,20 Years,Female,Full,30 Years,3.00,3.00,-15148.26,United States,2012,-17075.95
12254,Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries,"OBJECTIVE: To assess the cost effectiveness for tuberculosis (TB) screening of high-risk human immunodeficiency virus (HIV) positive pregnant women by using interferon-gamma release assays (IGRAs) compared to the tuberculin skin test (TST) in low TB incidence countries. METHODS: We constructed Markov models using a public health payer perspective. The target population was a hypothetical cohort of 20 year-olds HIV positive pregnant women until age 50 years in three most common screening situations; close contacts, immigrants from high burden countries and occasional screenings. BCG vaccination status was considered. Five strategies; TST, QuantiFERON(R)-TB Gold In-Tube (QFT), T-SPOT(R). TB (T-SPOT), TST followed by QFT and TST followed by T-SPOT were modeled. The main outcome measure of effectiveness was quality-adjusted life-years (QALYs) gained. The incremental cost effectiveness ratio (ICER) of each screening arm was applied and compared. RESULTS: In the base case analyses of close contacts, T-SPOT yielded the greatest benefits at the lowest cost. In the base case analyses of immigrants and occasional screenings, TST followed by QFT yielded the greatest benefits at the lowest cost. CONCLUSIONS: Using an IGRA for TB screening of high-risk HIV positive pregnant women is recommended on the basis of the cost effectiveness in low TB incidence countries.",2014-01-14232,23973660,J Infect,Akiko Kowada,2014,68 / 1,32-42,No,23973660,"Akiko Kowada; Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries, J Infect, ; 68(1):1532-2742; 32-42",QALY,Japan,Not Stated,Not Stated,Tuberculin Skin Test / QuantiFERON - TB Gold In-Tube vs. Tuberculin Skin Test / T-SPOT.Tuberculosis,pregnant women in immigrants from high burden countries. Non-BCG vaccinated during pregnancy,50 Years,20 Years,Female,Full,30 Years,3.00,3.00,-66030.3,United States,2012,-74432.99
12255,Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries,"OBJECTIVE: To assess the cost effectiveness for tuberculosis (TB) screening of high-risk human immunodeficiency virus (HIV) positive pregnant women by using interferon-gamma release assays (IGRAs) compared to the tuberculin skin test (TST) in low TB incidence countries. METHODS: We constructed Markov models using a public health payer perspective. The target population was a hypothetical cohort of 20 year-olds HIV positive pregnant women until age 50 years in three most common screening situations; close contacts, immigrants from high burden countries and occasional screenings. BCG vaccination status was considered. Five strategies; TST, QuantiFERON(R)-TB Gold In-Tube (QFT), T-SPOT(R). TB (T-SPOT), TST followed by QFT and TST followed by T-SPOT were modeled. The main outcome measure of effectiveness was quality-adjusted life-years (QALYs) gained. The incremental cost effectiveness ratio (ICER) of each screening arm was applied and compared. RESULTS: In the base case analyses of close contacts, T-SPOT yielded the greatest benefits at the lowest cost. In the base case analyses of immigrants and occasional screenings, TST followed by QFT yielded the greatest benefits at the lowest cost. CONCLUSIONS: Using an IGRA for TB screening of high-risk HIV positive pregnant women is recommended on the basis of the cost effectiveness in low TB incidence countries.",2014-01-14232,23973660,J Infect,Akiko Kowada,2014,68 / 1,32-42,No,23973660,"Akiko Kowada; Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries, J Infect, ; 68(1):1532-2742; 32-42",QALY,Japan,Not Stated,Not Stated,Tuberculin Skin Test / QuantiFERON - TB Gold In-Tube vs. Tuberculin Skin Test,pregnant women in immigrants from high burden countries. Non-BCG vaccinated during pregnancy,50 Years,20 Years,Female,Full,30 Years,3.00,3.00,-49712.54,United States,2012,-56038.72
12256,Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries,"OBJECTIVE: To assess the cost effectiveness for tuberculosis (TB) screening of high-risk human immunodeficiency virus (HIV) positive pregnant women by using interferon-gamma release assays (IGRAs) compared to the tuberculin skin test (TST) in low TB incidence countries. METHODS: We constructed Markov models using a public health payer perspective. The target population was a hypothetical cohort of 20 year-olds HIV positive pregnant women until age 50 years in three most common screening situations; close contacts, immigrants from high burden countries and occasional screenings. BCG vaccination status was considered. Five strategies; TST, QuantiFERON(R)-TB Gold In-Tube (QFT), T-SPOT(R). TB (T-SPOT), TST followed by QFT and TST followed by T-SPOT were modeled. The main outcome measure of effectiveness was quality-adjusted life-years (QALYs) gained. The incremental cost effectiveness ratio (ICER) of each screening arm was applied and compared. RESULTS: In the base case analyses of close contacts, T-SPOT yielded the greatest benefits at the lowest cost. In the base case analyses of immigrants and occasional screenings, TST followed by QFT yielded the greatest benefits at the lowest cost. CONCLUSIONS: Using an IGRA for TB screening of high-risk HIV positive pregnant women is recommended on the basis of the cost effectiveness in low TB incidence countries.",2014-01-14232,23973660,J Infect,Akiko Kowada,2014,68 / 1,32-42,No,23973660,"Akiko Kowada; Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries, J Infect, ; 68(1):1532-2742; 32-42",QALY,Japan,Not Stated,Not Stated,Tuberculin Skin Test / QuantiFERON - TB Gold In-Tube vs. QuantiFERON - TB Gold In-Tube,pregnant women in immigrants from high burden countries. Non-BCG vaccinated during pregnancy,50 Years,20 Years,Female,Full,30 Years,3.00,3.00,-49064.84,United States,2012,-55308.58
12257,Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries,"OBJECTIVE: To assess the cost effectiveness for tuberculosis (TB) screening of high-risk human immunodeficiency virus (HIV) positive pregnant women by using interferon-gamma release assays (IGRAs) compared to the tuberculin skin test (TST) in low TB incidence countries. METHODS: We constructed Markov models using a public health payer perspective. The target population was a hypothetical cohort of 20 year-olds HIV positive pregnant women until age 50 years in three most common screening situations; close contacts, immigrants from high burden countries and occasional screenings. BCG vaccination status was considered. Five strategies; TST, QuantiFERON(R)-TB Gold In-Tube (QFT), T-SPOT(R). TB (T-SPOT), TST followed by QFT and TST followed by T-SPOT were modeled. The main outcome measure of effectiveness was quality-adjusted life-years (QALYs) gained. The incremental cost effectiveness ratio (ICER) of each screening arm was applied and compared. RESULTS: In the base case analyses of close contacts, T-SPOT yielded the greatest benefits at the lowest cost. In the base case analyses of immigrants and occasional screenings, TST followed by QFT yielded the greatest benefits at the lowest cost. CONCLUSIONS: Using an IGRA for TB screening of high-risk HIV positive pregnant women is recommended on the basis of the cost effectiveness in low TB incidence countries.",2014-01-14232,23973660,J Infect,Akiko Kowada,2014,68 / 1,32-42,No,23973660,"Akiko Kowada; Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries, J Infect, ; 68(1):1532-2742; 32-42",QALY,Japan,Not Stated,Not Stated,Tuberculin Skin Test / QuantiFERON - TB Gold In-Tube vs. T-SPOT.Tuberculosis test,pregnant women in immigrants from high burden countries. Non-BCG vaccinated during pregnancy,50 Years,20 Years,Female,Full,30 Years,3.00,3.00,-54183.28,United States,2012,-61078.38
12258,Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries,"OBJECTIVE: To assess the cost effectiveness for tuberculosis (TB) screening of high-risk human immunodeficiency virus (HIV) positive pregnant women by using interferon-gamma release assays (IGRAs) compared to the tuberculin skin test (TST) in low TB incidence countries. METHODS: We constructed Markov models using a public health payer perspective. The target population was a hypothetical cohort of 20 year-olds HIV positive pregnant women until age 50 years in three most common screening situations; close contacts, immigrants from high burden countries and occasional screenings. BCG vaccination status was considered. Five strategies; TST, QuantiFERON(R)-TB Gold In-Tube (QFT), T-SPOT(R). TB (T-SPOT), TST followed by QFT and TST followed by T-SPOT were modeled. The main outcome measure of effectiveness was quality-adjusted life-years (QALYs) gained. The incremental cost effectiveness ratio (ICER) of each screening arm was applied and compared. RESULTS: In the base case analyses of close contacts, T-SPOT yielded the greatest benefits at the lowest cost. In the base case analyses of immigrants and occasional screenings, TST followed by QFT yielded the greatest benefits at the lowest cost. CONCLUSIONS: Using an IGRA for TB screening of high-risk HIV positive pregnant women is recommended on the basis of the cost effectiveness in low TB incidence countries.",2014-01-14232,23973660,J Infect,Akiko Kowada,2014,68 / 1,32-42,No,23973660,"Akiko Kowada; Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries, J Infect, ; 68(1):1532-2742; 32-42",QALY,Japan,Not Stated,Not Stated,Tuberculin Skin Test / QuantiFERON - TB Gold In-Tube vs. Tuberculin Skin Test / T-SPOT.Tuberculosis,pregnant women in immigrants from high burden countries. BCG vaccinated during pregnancy,50 Years,20 Years,Female,Full,30 Years,3.00,3.00,-50602.94,United States,2012,-57042.42
12259,Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries,"OBJECTIVE: To assess the cost effectiveness for tuberculosis (TB) screening of high-risk human immunodeficiency virus (HIV) positive pregnant women by using interferon-gamma release assays (IGRAs) compared to the tuberculin skin test (TST) in low TB incidence countries. METHODS: We constructed Markov models using a public health payer perspective. The target population was a hypothetical cohort of 20 year-olds HIV positive pregnant women until age 50 years in three most common screening situations; close contacts, immigrants from high burden countries and occasional screenings. BCG vaccination status was considered. Five strategies; TST, QuantiFERON(R)-TB Gold In-Tube (QFT), T-SPOT(R). TB (T-SPOT), TST followed by QFT and TST followed by T-SPOT were modeled. The main outcome measure of effectiveness was quality-adjusted life-years (QALYs) gained. The incremental cost effectiveness ratio (ICER) of each screening arm was applied and compared. RESULTS: In the base case analyses of close contacts, T-SPOT yielded the greatest benefits at the lowest cost. In the base case analyses of immigrants and occasional screenings, TST followed by QFT yielded the greatest benefits at the lowest cost. CONCLUSIONS: Using an IGRA for TB screening of high-risk HIV positive pregnant women is recommended on the basis of the cost effectiveness in low TB incidence countries.",2014-01-14232,23973660,J Infect,Akiko Kowada,2014,68 / 1,32-42,No,23973660,"Akiko Kowada; Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries, J Infect, ; 68(1):1532-2742; 32-42",QALY,Japan,Not Stated,Not Stated,Tuberculin Skin Test / QuantiFERON - TB Gold In-Tube vs. QuantiFERON - TB Gold In-Tube,pregnant women in immigrants from high burden countries. BCG vaccinated during pregnancy,50 Years,20 Years,Female,Full,30 Years,3.00,3.00,-46675.83,United States,2012,-52615.57
12260,Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries,"OBJECTIVE: To assess the cost effectiveness for tuberculosis (TB) screening of high-risk human immunodeficiency virus (HIV) positive pregnant women by using interferon-gamma release assays (IGRAs) compared to the tuberculin skin test (TST) in low TB incidence countries. METHODS: We constructed Markov models using a public health payer perspective. The target population was a hypothetical cohort of 20 year-olds HIV positive pregnant women until age 50 years in three most common screening situations; close contacts, immigrants from high burden countries and occasional screenings. BCG vaccination status was considered. Five strategies; TST, QuantiFERON(R)-TB Gold In-Tube (QFT), T-SPOT(R). TB (T-SPOT), TST followed by QFT and TST followed by T-SPOT were modeled. The main outcome measure of effectiveness was quality-adjusted life-years (QALYs) gained. The incremental cost effectiveness ratio (ICER) of each screening arm was applied and compared. RESULTS: In the base case analyses of close contacts, T-SPOT yielded the greatest benefits at the lowest cost. In the base case analyses of immigrants and occasional screenings, TST followed by QFT yielded the greatest benefits at the lowest cost. CONCLUSIONS: Using an IGRA for TB screening of high-risk HIV positive pregnant women is recommended on the basis of the cost effectiveness in low TB incidence countries.",2014-01-14232,23973660,J Infect,Akiko Kowada,2014,68 / 1,32-42,No,23973660,"Akiko Kowada; Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries, J Infect, ; 68(1):1532-2742; 32-42",QALY,Japan,Not Stated,Not Stated,Tuberculin Skin Test / QuantiFERON - TB Gold In-Tube vs. T-SPOT.Tuberculosis,pregnant women in immigrants from high burden countries. BCG vaccinated during pregnancy,50 Years,20 Years,Female,Full,30 Years,3.00,3.00,-52199.79,United States,2012,-58842.48
12261,Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries,"OBJECTIVE: To assess the cost effectiveness for tuberculosis (TB) screening of high-risk human immunodeficiency virus (HIV) positive pregnant women by using interferon-gamma release assays (IGRAs) compared to the tuberculin skin test (TST) in low TB incidence countries. METHODS: We constructed Markov models using a public health payer perspective. The target population was a hypothetical cohort of 20 year-olds HIV positive pregnant women until age 50 years in three most common screening situations; close contacts, immigrants from high burden countries and occasional screenings. BCG vaccination status was considered. Five strategies; TST, QuantiFERON(R)-TB Gold In-Tube (QFT), T-SPOT(R). TB (T-SPOT), TST followed by QFT and TST followed by T-SPOT were modeled. The main outcome measure of effectiveness was quality-adjusted life-years (QALYs) gained. The incremental cost effectiveness ratio (ICER) of each screening arm was applied and compared. RESULTS: In the base case analyses of close contacts, T-SPOT yielded the greatest benefits at the lowest cost. In the base case analyses of immigrants and occasional screenings, TST followed by QFT yielded the greatest benefits at the lowest cost. CONCLUSIONS: Using an IGRA for TB screening of high-risk HIV positive pregnant women is recommended on the basis of the cost effectiveness in low TB incidence countries.",2014-01-14232,23973660,J Infect,Akiko Kowada,2014,68 / 1,32-42,No,23973660,"Akiko Kowada; Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries, J Infect, ; 68(1):1532-2742; 32-42",QALY,Japan,Not Stated,Not Stated,Tuberculin Skin Test / QuantiFERON - TB Gold In-Tube vs. Tuberculin Skin Test,pregnant women in immigrants from high burden countries. BCG vaccinated during pregnancy,50 Years,20 Years,Female,Full,30 Years,3.00,3.00,-28415.41,United States,2012,-32031.42
12262,Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries,"OBJECTIVE: To assess the cost effectiveness for tuberculosis (TB) screening of high-risk human immunodeficiency virus (HIV) positive pregnant women by using interferon-gamma release assays (IGRAs) compared to the tuberculin skin test (TST) in low TB incidence countries. METHODS: We constructed Markov models using a public health payer perspective. The target population was a hypothetical cohort of 20 year-olds HIV positive pregnant women until age 50 years in three most common screening situations; close contacts, immigrants from high burden countries and occasional screenings. BCG vaccination status was considered. Five strategies; TST, QuantiFERON(R)-TB Gold In-Tube (QFT), T-SPOT(R). TB (T-SPOT), TST followed by QFT and TST followed by T-SPOT were modeled. The main outcome measure of effectiveness was quality-adjusted life-years (QALYs) gained. The incremental cost effectiveness ratio (ICER) of each screening arm was applied and compared. RESULTS: In the base case analyses of close contacts, T-SPOT yielded the greatest benefits at the lowest cost. In the base case analyses of immigrants and occasional screenings, TST followed by QFT yielded the greatest benefits at the lowest cost. CONCLUSIONS: Using an IGRA for TB screening of high-risk HIV positive pregnant women is recommended on the basis of the cost effectiveness in low TB incidence countries.",2014-01-14232,23973660,J Infect,Akiko Kowada,2014,68 / 1,32-42,No,23973660,"Akiko Kowada; Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries, J Infect, ; 68(1):1532-2742; 32-42",QALY,Japan,Not Stated,Not Stated,Tuberculin Skin Test / QuantiFERON - TB Gold In-Tube vs. Tuberculin Skin Test / T-SPOT.Tuberculosis,pregnant women in immigrants from high burden countries. Non-BCG vaccinated cohort in postpartum period,50 Years,20 Years,Female,Full,30 Years,3.00,3.00,-68212.77,United States,2012,-76893.19
12263,Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries,"OBJECTIVE: To assess the cost effectiveness for tuberculosis (TB) screening of high-risk human immunodeficiency virus (HIV) positive pregnant women by using interferon-gamma release assays (IGRAs) compared to the tuberculin skin test (TST) in low TB incidence countries. METHODS: We constructed Markov models using a public health payer perspective. The target population was a hypothetical cohort of 20 year-olds HIV positive pregnant women until age 50 years in three most common screening situations; close contacts, immigrants from high burden countries and occasional screenings. BCG vaccination status was considered. Five strategies; TST, QuantiFERON(R)-TB Gold In-Tube (QFT), T-SPOT(R). TB (T-SPOT), TST followed by QFT and TST followed by T-SPOT were modeled. The main outcome measure of effectiveness was quality-adjusted life-years (QALYs) gained. The incremental cost effectiveness ratio (ICER) of each screening arm was applied and compared. RESULTS: In the base case analyses of close contacts, T-SPOT yielded the greatest benefits at the lowest cost. In the base case analyses of immigrants and occasional screenings, TST followed by QFT yielded the greatest benefits at the lowest cost. CONCLUSIONS: Using an IGRA for TB screening of high-risk HIV positive pregnant women is recommended on the basis of the cost effectiveness in low TB incidence countries.",2014-01-14232,23973660,J Infect,Akiko Kowada,2014,68 / 1,32-42,No,23973660,"Akiko Kowada; Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries, J Infect, ; 68(1):1532-2742; 32-42",QALY,Japan,Not Stated,Not Stated,Tuberculin Skin Test / QuantiFERON - TB Gold In-Tube vs. Tuberculin Skin Test,pregnant women in immigrants from high burden countries. Non-BCG vaccinated cohort in postpartum period,50 Years,20 Years,Female,Full,30 Years,3.00,3.00,-54885.8,United States,2012,-61870.3
12264,Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries,"OBJECTIVE: To assess the cost effectiveness for tuberculosis (TB) screening of high-risk human immunodeficiency virus (HIV) positive pregnant women by using interferon-gamma release assays (IGRAs) compared to the tuberculin skin test (TST) in low TB incidence countries. METHODS: We constructed Markov models using a public health payer perspective. The target population was a hypothetical cohort of 20 year-olds HIV positive pregnant women until age 50 years in three most common screening situations; close contacts, immigrants from high burden countries and occasional screenings. BCG vaccination status was considered. Five strategies; TST, QuantiFERON(R)-TB Gold In-Tube (QFT), T-SPOT(R). TB (T-SPOT), TST followed by QFT and TST followed by T-SPOT were modeled. The main outcome measure of effectiveness was quality-adjusted life-years (QALYs) gained. The incremental cost effectiveness ratio (ICER) of each screening arm was applied and compared. RESULTS: In the base case analyses of close contacts, T-SPOT yielded the greatest benefits at the lowest cost. In the base case analyses of immigrants and occasional screenings, TST followed by QFT yielded the greatest benefits at the lowest cost. CONCLUSIONS: Using an IGRA for TB screening of high-risk HIV positive pregnant women is recommended on the basis of the cost effectiveness in low TB incidence countries.",2014-01-14232,23973660,J Infect,Akiko Kowada,2014,68 / 1,32-42,No,23973660,"Akiko Kowada; Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries, J Infect, ; 68(1):1532-2742; 32-42",QALY,Japan,Not Stated,Not Stated,Tuberculin Skin Test / QuantiFERON - TB Gold In-Tube vs. QuantiFERON - TB Gold In-Tube,pregnant women in immigrants from high burden countries. Non-BCG vaccinated cohort in postpartum period,50 Years,20 Years,Female,Full,30 Years,3.00,3.00,-58163.95,United States,2012,-65565.61
12265,Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries,"OBJECTIVE: To assess the cost effectiveness for tuberculosis (TB) screening of high-risk human immunodeficiency virus (HIV) positive pregnant women by using interferon-gamma release assays (IGRAs) compared to the tuberculin skin test (TST) in low TB incidence countries. METHODS: We constructed Markov models using a public health payer perspective. The target population was a hypothetical cohort of 20 year-olds HIV positive pregnant women until age 50 years in three most common screening situations; close contacts, immigrants from high burden countries and occasional screenings. BCG vaccination status was considered. Five strategies; TST, QuantiFERON(R)-TB Gold In-Tube (QFT), T-SPOT(R). TB (T-SPOT), TST followed by QFT and TST followed by T-SPOT were modeled. The main outcome measure of effectiveness was quality-adjusted life-years (QALYs) gained. The incremental cost effectiveness ratio (ICER) of each screening arm was applied and compared. RESULTS: In the base case analyses of close contacts, T-SPOT yielded the greatest benefits at the lowest cost. In the base case analyses of immigrants and occasional screenings, TST followed by QFT yielded the greatest benefits at the lowest cost. CONCLUSIONS: Using an IGRA for TB screening of high-risk HIV positive pregnant women is recommended on the basis of the cost effectiveness in low TB incidence countries.",2014-01-14232,23973660,J Infect,Akiko Kowada,2014,68 / 1,32-42,No,23973660,"Akiko Kowada; Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries, J Infect, ; 68(1):1532-2742; 32-42",QALY,Japan,Not Stated,Not Stated,Tuberculin Skin Test / QuantiFERON - TB Gold In-Tube vs. T-SPOT.Tuberculosis,pregnant women in immigrants from high burden countries. Non-BCG vaccinated cohort in postpartum period,50 Years,20 Years,Female,Full,30 Years,3.00,3.00,-59281.52,United States,2012,-66825.4
12266,Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries,"OBJECTIVE: To assess the cost effectiveness for tuberculosis (TB) screening of high-risk human immunodeficiency virus (HIV) positive pregnant women by using interferon-gamma release assays (IGRAs) compared to the tuberculin skin test (TST) in low TB incidence countries. METHODS: We constructed Markov models using a public health payer perspective. The target population was a hypothetical cohort of 20 year-olds HIV positive pregnant women until age 50 years in three most common screening situations; close contacts, immigrants from high burden countries and occasional screenings. BCG vaccination status was considered. Five strategies; TST, QuantiFERON(R)-TB Gold In-Tube (QFT), T-SPOT(R). TB (T-SPOT), TST followed by QFT and TST followed by T-SPOT were modeled. The main outcome measure of effectiveness was quality-adjusted life-years (QALYs) gained. The incremental cost effectiveness ratio (ICER) of each screening arm was applied and compared. RESULTS: In the base case analyses of close contacts, T-SPOT yielded the greatest benefits at the lowest cost. In the base case analyses of immigrants and occasional screenings, TST followed by QFT yielded the greatest benefits at the lowest cost. CONCLUSIONS: Using an IGRA for TB screening of high-risk HIV positive pregnant women is recommended on the basis of the cost effectiveness in low TB incidence countries.",2014-01-14232,23973660,J Infect,Akiko Kowada,2014,68 / 1,32-42,No,23973660,"Akiko Kowada; Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries, J Infect, ; 68(1):1532-2742; 32-42",QALY,Japan,Not Stated,Not Stated,Tuberculin Skin Test / QuantiFERON - TB Gold In-Tube vs. Tuberculin Skin Test / T-SPOT.Tuberculosis,pregnant women in immigrants from high burden countries. BCG vaccinated cohort in postpartum period,50 Years,20 Years,Female,Full,30 Years,3.00,3.00,-56684.93,United States,2012,-63898.38
12267,Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries,"OBJECTIVE: To assess the cost effectiveness for tuberculosis (TB) screening of high-risk human immunodeficiency virus (HIV) positive pregnant women by using interferon-gamma release assays (IGRAs) compared to the tuberculin skin test (TST) in low TB incidence countries. METHODS: We constructed Markov models using a public health payer perspective. The target population was a hypothetical cohort of 20 year-olds HIV positive pregnant women until age 50 years in three most common screening situations; close contacts, immigrants from high burden countries and occasional screenings. BCG vaccination status was considered. Five strategies; TST, QuantiFERON(R)-TB Gold In-Tube (QFT), T-SPOT(R). TB (T-SPOT), TST followed by QFT and TST followed by T-SPOT were modeled. The main outcome measure of effectiveness was quality-adjusted life-years (QALYs) gained. The incremental cost effectiveness ratio (ICER) of each screening arm was applied and compared. RESULTS: In the base case analyses of close contacts, T-SPOT yielded the greatest benefits at the lowest cost. In the base case analyses of immigrants and occasional screenings, TST followed by QFT yielded the greatest benefits at the lowest cost. CONCLUSIONS: Using an IGRA for TB screening of high-risk HIV positive pregnant women is recommended on the basis of the cost effectiveness in low TB incidence countries.",2014-01-14232,23973660,J Infect,Akiko Kowada,2014,68 / 1,32-42,No,23973660,"Akiko Kowada; Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries, J Infect, ; 68(1):1532-2742; 32-42",QALY,Japan,Not Stated,Not Stated,Tuberculin Skin Test / QuantiFERON - TB Gold In-Tube vs. QuantiFERON - TB Gold In-Tube,pregnant women in immigrants from high burden countries. BCG vaccinated cohort in postpartum period,50 Years,20 Years,Female,Full,30 Years,3.00,3.00,-56961.9,United States,2012,-64210.59
12268,Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries,"OBJECTIVE: To assess the cost effectiveness for tuberculosis (TB) screening of high-risk human immunodeficiency virus (HIV) positive pregnant women by using interferon-gamma release assays (IGRAs) compared to the tuberculin skin test (TST) in low TB incidence countries. METHODS: We constructed Markov models using a public health payer perspective. The target population was a hypothetical cohort of 20 year-olds HIV positive pregnant women until age 50 years in three most common screening situations; close contacts, immigrants from high burden countries and occasional screenings. BCG vaccination status was considered. Five strategies; TST, QuantiFERON(R)-TB Gold In-Tube (QFT), T-SPOT(R). TB (T-SPOT), TST followed by QFT and TST followed by T-SPOT were modeled. The main outcome measure of effectiveness was quality-adjusted life-years (QALYs) gained. The incremental cost effectiveness ratio (ICER) of each screening arm was applied and compared. RESULTS: In the base case analyses of close contacts, T-SPOT yielded the greatest benefits at the lowest cost. In the base case analyses of immigrants and occasional screenings, TST followed by QFT yielded the greatest benefits at the lowest cost. CONCLUSIONS: Using an IGRA for TB screening of high-risk HIV positive pregnant women is recommended on the basis of the cost effectiveness in low TB incidence countries.",2014-01-14232,23973660,J Infect,Akiko Kowada,2014,68 / 1,32-42,No,23973660,"Akiko Kowada; Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries, J Infect, ; 68(1):1532-2742; 32-42",QALY,Japan,Not Stated,Not Stated,Tuberculin Skin Test / QuantiFERON - TB Gold In-Tube vs. T-SPOT.Tuberculosis,pregnant women in immigrants from high burden countries. BCG vaccinated cohort in postpartum period,50 Years,20 Years,Female,Full,30 Years,3.00,3.00,-58305.19,United States,2012,-65724.83
12269,Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries,"OBJECTIVE: To assess the cost effectiveness for tuberculosis (TB) screening of high-risk human immunodeficiency virus (HIV) positive pregnant women by using interferon-gamma release assays (IGRAs) compared to the tuberculin skin test (TST) in low TB incidence countries. METHODS: We constructed Markov models using a public health payer perspective. The target population was a hypothetical cohort of 20 year-olds HIV positive pregnant women until age 50 years in three most common screening situations; close contacts, immigrants from high burden countries and occasional screenings. BCG vaccination status was considered. Five strategies; TST, QuantiFERON(R)-TB Gold In-Tube (QFT), T-SPOT(R). TB (T-SPOT), TST followed by QFT and TST followed by T-SPOT were modeled. The main outcome measure of effectiveness was quality-adjusted life-years (QALYs) gained. The incremental cost effectiveness ratio (ICER) of each screening arm was applied and compared. RESULTS: In the base case analyses of close contacts, T-SPOT yielded the greatest benefits at the lowest cost. In the base case analyses of immigrants and occasional screenings, TST followed by QFT yielded the greatest benefits at the lowest cost. CONCLUSIONS: Using an IGRA for TB screening of high-risk HIV positive pregnant women is recommended on the basis of the cost effectiveness in low TB incidence countries.",2014-01-14232,23973660,J Infect,Akiko Kowada,2014,68 / 1,32-42,No,23973660,"Akiko Kowada; Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries, J Infect, ; 68(1):1532-2742; 32-42",QALY,Japan,Not Stated,Not Stated,Tuberculin Skin Test / QuantiFERON - TB Gold In-Tube vs. Tuberculin Skin Test,pregnant women in immigrants from high burden countries. BCG vaccinated cohort in postpartum period,50 Years,20 Years,Female,Full,30 Years,3.00,3.00,-29598,United States,2012,-33364.5
12270,Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries,"OBJECTIVE: To assess the cost effectiveness for tuberculosis (TB) screening of high-risk human immunodeficiency virus (HIV) positive pregnant women by using interferon-gamma release assays (IGRAs) compared to the tuberculin skin test (TST) in low TB incidence countries. METHODS: We constructed Markov models using a public health payer perspective. The target population was a hypothetical cohort of 20 year-olds HIV positive pregnant women until age 50 years in three most common screening situations; close contacts, immigrants from high burden countries and occasional screenings. BCG vaccination status was considered. Five strategies; TST, QuantiFERON(R)-TB Gold In-Tube (QFT), T-SPOT(R). TB (T-SPOT), TST followed by QFT and TST followed by T-SPOT were modeled. The main outcome measure of effectiveness was quality-adjusted life-years (QALYs) gained. The incremental cost effectiveness ratio (ICER) of each screening arm was applied and compared. RESULTS: In the base case analyses of close contacts, T-SPOT yielded the greatest benefits at the lowest cost. In the base case analyses of immigrants and occasional screenings, TST followed by QFT yielded the greatest benefits at the lowest cost. CONCLUSIONS: Using an IGRA for TB screening of high-risk HIV positive pregnant women is recommended on the basis of the cost effectiveness in low TB incidence countries.",2014-01-14232,23973660,J Infect,Akiko Kowada,2014,68 / 1,32-42,No,23973660,"Akiko Kowada; Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries, J Infect, ; 68(1):1532-2742; 32-42",QALY,Japan,Not Stated,Not Stated,Tuberculin Skin Test / QuantiFERON - TB Gold In-Tube vs. Tuberculin Skin Test / T-SPOT.Tuberculosis,"pregnant women, non-BCG vaccinated during pregnancy",50 Years,20 Years,Female,Full,30 Years,3.00,3.00,-42000,United States,2012,-47344.71
12271,Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries,"OBJECTIVE: To assess the cost effectiveness for tuberculosis (TB) screening of high-risk human immunodeficiency virus (HIV) positive pregnant women by using interferon-gamma release assays (IGRAs) compared to the tuberculin skin test (TST) in low TB incidence countries. METHODS: We constructed Markov models using a public health payer perspective. The target population was a hypothetical cohort of 20 year-olds HIV positive pregnant women until age 50 years in three most common screening situations; close contacts, immigrants from high burden countries and occasional screenings. BCG vaccination status was considered. Five strategies; TST, QuantiFERON(R)-TB Gold In-Tube (QFT), T-SPOT(R). TB (T-SPOT), TST followed by QFT and TST followed by T-SPOT were modeled. The main outcome measure of effectiveness was quality-adjusted life-years (QALYs) gained. The incremental cost effectiveness ratio (ICER) of each screening arm was applied and compared. RESULTS: In the base case analyses of close contacts, T-SPOT yielded the greatest benefits at the lowest cost. In the base case analyses of immigrants and occasional screenings, TST followed by QFT yielded the greatest benefits at the lowest cost. CONCLUSIONS: Using an IGRA for TB screening of high-risk HIV positive pregnant women is recommended on the basis of the cost effectiveness in low TB incidence countries.",2014-01-14232,23973660,J Infect,Akiko Kowada,2014,68 / 1,32-42,No,23973660,"Akiko Kowada; Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries, J Infect, ; 68(1):1532-2742; 32-42",QALY,Japan,Not Stated,Not Stated,Tuberculin Skin Test / QuantiFERON - TB Gold In-Tube vs. QuantiFERON - TB Gold In-Tube,"pregnant women, non-BCG vaccinated during pregnancy",50 Years,20 Years,Female,Full,30 Years,3.00,3.00,-19261.44,United States,2012,-21712.55
12272,Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries,"OBJECTIVE: To assess the cost effectiveness for tuberculosis (TB) screening of high-risk human immunodeficiency virus (HIV) positive pregnant women by using interferon-gamma release assays (IGRAs) compared to the tuberculin skin test (TST) in low TB incidence countries. METHODS: We constructed Markov models using a public health payer perspective. The target population was a hypothetical cohort of 20 year-olds HIV positive pregnant women until age 50 years in three most common screening situations; close contacts, immigrants from high burden countries and occasional screenings. BCG vaccination status was considered. Five strategies; TST, QuantiFERON(R)-TB Gold In-Tube (QFT), T-SPOT(R). TB (T-SPOT), TST followed by QFT and TST followed by T-SPOT were modeled. The main outcome measure of effectiveness was quality-adjusted life-years (QALYs) gained. The incremental cost effectiveness ratio (ICER) of each screening arm was applied and compared. RESULTS: In the base case analyses of close contacts, T-SPOT yielded the greatest benefits at the lowest cost. In the base case analyses of immigrants and occasional screenings, TST followed by QFT yielded the greatest benefits at the lowest cost. CONCLUSIONS: Using an IGRA for TB screening of high-risk HIV positive pregnant women is recommended on the basis of the cost effectiveness in low TB incidence countries.",2014-01-14232,23973660,J Infect,Akiko Kowada,2014,68 / 1,32-42,No,23973660,"Akiko Kowada; Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries, J Infect, ; 68(1):1532-2742; 32-42",QALY,Japan,Not Stated,Not Stated,Tuberculin Skin Test / QuantiFERON - TB Gold In-Tube vs. Tuberculin Skin Test,"pregnant women, non-BCG vaccinated during pregnancy",50 Years,20 Years,Female,Full,30 Years,3.00,3.00,-35316.05,United States,2012,-39810.2
12273,Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries,"OBJECTIVE: To assess the cost effectiveness for tuberculosis (TB) screening of high-risk human immunodeficiency virus (HIV) positive pregnant women by using interferon-gamma release assays (IGRAs) compared to the tuberculin skin test (TST) in low TB incidence countries. METHODS: We constructed Markov models using a public health payer perspective. The target population was a hypothetical cohort of 20 year-olds HIV positive pregnant women until age 50 years in three most common screening situations; close contacts, immigrants from high burden countries and occasional screenings. BCG vaccination status was considered. Five strategies; TST, QuantiFERON(R)-TB Gold In-Tube (QFT), T-SPOT(R). TB (T-SPOT), TST followed by QFT and TST followed by T-SPOT were modeled. The main outcome measure of effectiveness was quality-adjusted life-years (QALYs) gained. The incremental cost effectiveness ratio (ICER) of each screening arm was applied and compared. RESULTS: In the base case analyses of close contacts, T-SPOT yielded the greatest benefits at the lowest cost. In the base case analyses of immigrants and occasional screenings, TST followed by QFT yielded the greatest benefits at the lowest cost. CONCLUSIONS: Using an IGRA for TB screening of high-risk HIV positive pregnant women is recommended on the basis of the cost effectiveness in low TB incidence countries.",2014-01-14232,23973660,J Infect,Akiko Kowada,2014,68 / 1,32-42,No,23973660,"Akiko Kowada; Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries, J Infect, ; 68(1):1532-2742; 32-42",QALY,Japan,Not Stated,Not Stated,Tuberculin Skin Test / QuantiFERON - TB Gold In-Tube vs. T-SPOT.Tuberculosis,"pregnant women, non-BCG vaccinated during pregnancy",50 Years,20 Years,Female,Full,30 Years,3.00,3.00,-35739.85,United States,2012,-40287.92
12274,Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries,"OBJECTIVE: To assess the cost effectiveness for tuberculosis (TB) screening of high-risk human immunodeficiency virus (HIV) positive pregnant women by using interferon-gamma release assays (IGRAs) compared to the tuberculin skin test (TST) in low TB incidence countries. METHODS: We constructed Markov models using a public health payer perspective. The target population was a hypothetical cohort of 20 year-olds HIV positive pregnant women until age 50 years in three most common screening situations; close contacts, immigrants from high burden countries and occasional screenings. BCG vaccination status was considered. Five strategies; TST, QuantiFERON(R)-TB Gold In-Tube (QFT), T-SPOT(R). TB (T-SPOT), TST followed by QFT and TST followed by T-SPOT were modeled. The main outcome measure of effectiveness was quality-adjusted life-years (QALYs) gained. The incremental cost effectiveness ratio (ICER) of each screening arm was applied and compared. RESULTS: In the base case analyses of close contacts, T-SPOT yielded the greatest benefits at the lowest cost. In the base case analyses of immigrants and occasional screenings, TST followed by QFT yielded the greatest benefits at the lowest cost. CONCLUSIONS: Using an IGRA for TB screening of high-risk HIV positive pregnant women is recommended on the basis of the cost effectiveness in low TB incidence countries.",2014-01-14232,23973660,J Infect,Akiko Kowada,2014,68 / 1,32-42,No,23973660,"Akiko Kowada; Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries, J Infect, ; 68(1):1532-2742; 32-42",QALY,Japan,Not Stated,Not Stated,Tuberculin Skin Test / QuantiFERON - TB Gold In-Tube vs. Tuberculin Skin Test / T-SPOT.Tuberculosis test,"pregnant women, BCG vaccinated during pregnancy",50 Years,20 Years,Female,Full,30 Years,3.00,3.00,-35688.31,United States,2012,-40229.83
12275,Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries,"OBJECTIVE: To assess the cost effectiveness for tuberculosis (TB) screening of high-risk human immunodeficiency virus (HIV) positive pregnant women by using interferon-gamma release assays (IGRAs) compared to the tuberculin skin test (TST) in low TB incidence countries. METHODS: We constructed Markov models using a public health payer perspective. The target population was a hypothetical cohort of 20 year-olds HIV positive pregnant women until age 50 years in three most common screening situations; close contacts, immigrants from high burden countries and occasional screenings. BCG vaccination status was considered. Five strategies; TST, QuantiFERON(R)-TB Gold In-Tube (QFT), T-SPOT(R). TB (T-SPOT), TST followed by QFT and TST followed by T-SPOT were modeled. The main outcome measure of effectiveness was quality-adjusted life-years (QALYs) gained. The incremental cost effectiveness ratio (ICER) of each screening arm was applied and compared. RESULTS: In the base case analyses of close contacts, T-SPOT yielded the greatest benefits at the lowest cost. In the base case analyses of immigrants and occasional screenings, TST followed by QFT yielded the greatest benefits at the lowest cost. CONCLUSIONS: Using an IGRA for TB screening of high-risk HIV positive pregnant women is recommended on the basis of the cost effectiveness in low TB incidence countries.",2014-01-14232,23973660,J Infect,Akiko Kowada,2014,68 / 1,32-42,No,23973660,"Akiko Kowada; Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries, J Infect, ; 68(1):1532-2742; 32-42",QALY,Japan,Not Stated,Not Stated,Tuberculin Skin Test / QuantiFERON - TB Gold In-Tube vs. QuantiFERON - TB Gold In-Tube,"pregnant women, BCG vaccinated during pregnancy",50 Years,20 Years,Female,Full,30 Years,3.00,3.00,-15066.93,United States,2012,-16984.27
12276,Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries,"OBJECTIVE: To assess the cost effectiveness for tuberculosis (TB) screening of high-risk human immunodeficiency virus (HIV) positive pregnant women by using interferon-gamma release assays (IGRAs) compared to the tuberculin skin test (TST) in low TB incidence countries. METHODS: We constructed Markov models using a public health payer perspective. The target population was a hypothetical cohort of 20 year-olds HIV positive pregnant women until age 50 years in three most common screening situations; close contacts, immigrants from high burden countries and occasional screenings. BCG vaccination status was considered. Five strategies; TST, QuantiFERON(R)-TB Gold In-Tube (QFT), T-SPOT(R). TB (T-SPOT), TST followed by QFT and TST followed by T-SPOT were modeled. The main outcome measure of effectiveness was quality-adjusted life-years (QALYs) gained. The incremental cost effectiveness ratio (ICER) of each screening arm was applied and compared. RESULTS: In the base case analyses of close contacts, T-SPOT yielded the greatest benefits at the lowest cost. In the base case analyses of immigrants and occasional screenings, TST followed by QFT yielded the greatest benefits at the lowest cost. CONCLUSIONS: Using an IGRA for TB screening of high-risk HIV positive pregnant women is recommended on the basis of the cost effectiveness in low TB incidence countries.",2014-01-14232,23973660,J Infect,Akiko Kowada,2014,68 / 1,32-42,No,23973660,"Akiko Kowada; Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries, J Infect, ; 68(1):1532-2742; 32-42",QALY,Japan,Not Stated,Not Stated,Tuberculin Skin Test / QuantiFERON - TB Gold In-Tube vs. T-SPOT.Tuberculosis,"pregnant women, BCG vaccinated during pregnancy",50 Years,20 Years,Female,Full,30 Years,3.00,3.00,-31204.92,United States,2012,-35175.9
12277,Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries,"OBJECTIVE: To assess the cost effectiveness for tuberculosis (TB) screening of high-risk human immunodeficiency virus (HIV) positive pregnant women by using interferon-gamma release assays (IGRAs) compared to the tuberculin skin test (TST) in low TB incidence countries. METHODS: We constructed Markov models using a public health payer perspective. The target population was a hypothetical cohort of 20 year-olds HIV positive pregnant women until age 50 years in three most common screening situations; close contacts, immigrants from high burden countries and occasional screenings. BCG vaccination status was considered. Five strategies; TST, QuantiFERON(R)-TB Gold In-Tube (QFT), T-SPOT(R). TB (T-SPOT), TST followed by QFT and TST followed by T-SPOT were modeled. The main outcome measure of effectiveness was quality-adjusted life-years (QALYs) gained. The incremental cost effectiveness ratio (ICER) of each screening arm was applied and compared. RESULTS: In the base case analyses of close contacts, T-SPOT yielded the greatest benefits at the lowest cost. In the base case analyses of immigrants and occasional screenings, TST followed by QFT yielded the greatest benefits at the lowest cost. CONCLUSIONS: Using an IGRA for TB screening of high-risk HIV positive pregnant women is recommended on the basis of the cost effectiveness in low TB incidence countries.",2014-01-14232,23973660,J Infect,Akiko Kowada,2014,68 / 1,32-42,No,23973660,"Akiko Kowada; Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries, J Infect, ; 68(1):1532-2742; 32-42",QALY,Japan,Not Stated,Not Stated,Tuberculin Skin Test / QuantiFERON - TB Gold In-Tube vs. Tuberculin Skin Test,"pregnant women, BCG vaccinated during pregnancy",50 Years,20 Years,Female,Full,30 Years,3.00,3.00,-28026.48,United States,2012,-31592.99
12278,Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries,"OBJECTIVE: To assess the cost effectiveness for tuberculosis (TB) screening of high-risk human immunodeficiency virus (HIV) positive pregnant women by using interferon-gamma release assays (IGRAs) compared to the tuberculin skin test (TST) in low TB incidence countries. METHODS: We constructed Markov models using a public health payer perspective. The target population was a hypothetical cohort of 20 year-olds HIV positive pregnant women until age 50 years in three most common screening situations; close contacts, immigrants from high burden countries and occasional screenings. BCG vaccination status was considered. Five strategies; TST, QuantiFERON(R)-TB Gold In-Tube (QFT), T-SPOT(R). TB (T-SPOT), TST followed by QFT and TST followed by T-SPOT were modeled. The main outcome measure of effectiveness was quality-adjusted life-years (QALYs) gained. The incremental cost effectiveness ratio (ICER) of each screening arm was applied and compared. RESULTS: In the base case analyses of close contacts, T-SPOT yielded the greatest benefits at the lowest cost. In the base case analyses of immigrants and occasional screenings, TST followed by QFT yielded the greatest benefits at the lowest cost. CONCLUSIONS: Using an IGRA for TB screening of high-risk HIV positive pregnant women is recommended on the basis of the cost effectiveness in low TB incidence countries.",2014-01-14232,23973660,J Infect,Akiko Kowada,2014,68 / 1,32-42,No,23973660,"Akiko Kowada; Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries, J Infect, ; 68(1):1532-2742; 32-42",QALY,Japan,Not Stated,Not Stated,Tuberculin Skin Test / QuantiFERON - TB Gold In-Tube vs. Tuberculin Skin Test / T-SPOT.Tuberculosis,"pregnant women, Non-BCG vaccinated in postpartum period",50 Years,20 Years,Female,Full,30 Years,3.00,3.00,-42000,United States,2012,-47344.71
12279,Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries,"OBJECTIVE: To assess the cost effectiveness for tuberculosis (TB) screening of high-risk human immunodeficiency virus (HIV) positive pregnant women by using interferon-gamma release assays (IGRAs) compared to the tuberculin skin test (TST) in low TB incidence countries. METHODS: We constructed Markov models using a public health payer perspective. The target population was a hypothetical cohort of 20 year-olds HIV positive pregnant women until age 50 years in three most common screening situations; close contacts, immigrants from high burden countries and occasional screenings. BCG vaccination status was considered. Five strategies; TST, QuantiFERON(R)-TB Gold In-Tube (QFT), T-SPOT(R). TB (T-SPOT), TST followed by QFT and TST followed by T-SPOT were modeled. The main outcome measure of effectiveness was quality-adjusted life-years (QALYs) gained. The incremental cost effectiveness ratio (ICER) of each screening arm was applied and compared. RESULTS: In the base case analyses of close contacts, T-SPOT yielded the greatest benefits at the lowest cost. In the base case analyses of immigrants and occasional screenings, TST followed by QFT yielded the greatest benefits at the lowest cost. CONCLUSIONS: Using an IGRA for TB screening of high-risk HIV positive pregnant women is recommended on the basis of the cost effectiveness in low TB incidence countries.",2014-01-14232,23973660,J Infect,Akiko Kowada,2014,68 / 1,32-42,No,23973660,"Akiko Kowada; Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries, J Infect, ; 68(1):1532-2742; 32-42",QALY,Japan,Not Stated,Not Stated,Tuberculin Skin Test / QuantiFERON - TB Gold In-Tube vs. QuantiFERON - TB Gold In-Tube,"pregnant women, Non-BCG vaccinated in postpartum period",50 Years,20 Years,Female,Full,30 Years,3.00,3.00,-19261.44,United States,2012,-21712.55
12280,Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries,"OBJECTIVE: To assess the cost effectiveness for tuberculosis (TB) screening of high-risk human immunodeficiency virus (HIV) positive pregnant women by using interferon-gamma release assays (IGRAs) compared to the tuberculin skin test (TST) in low TB incidence countries. METHODS: We constructed Markov models using a public health payer perspective. The target population was a hypothetical cohort of 20 year-olds HIV positive pregnant women until age 50 years in three most common screening situations; close contacts, immigrants from high burden countries and occasional screenings. BCG vaccination status was considered. Five strategies; TST, QuantiFERON(R)-TB Gold In-Tube (QFT), T-SPOT(R). TB (T-SPOT), TST followed by QFT and TST followed by T-SPOT were modeled. The main outcome measure of effectiveness was quality-adjusted life-years (QALYs) gained. The incremental cost effectiveness ratio (ICER) of each screening arm was applied and compared. RESULTS: In the base case analyses of close contacts, T-SPOT yielded the greatest benefits at the lowest cost. In the base case analyses of immigrants and occasional screenings, TST followed by QFT yielded the greatest benefits at the lowest cost. CONCLUSIONS: Using an IGRA for TB screening of high-risk HIV positive pregnant women is recommended on the basis of the cost effectiveness in low TB incidence countries.",2014-01-14232,23973660,J Infect,Akiko Kowada,2014,68 / 1,32-42,No,23973660,"Akiko Kowada; Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries, J Infect, ; 68(1):1532-2742; 32-42",QALY,Japan,Not Stated,Not Stated,Tuberculin Skin Test / QuantiFERON - TB Gold In-Tube vs. Tuberculin Skin Test,"pregnant women, Non-BCG vaccinated in postpartum period",50 Years,20 Years,Female,Full,30 Years,3.00,3.00,-35316.05,United States,2012,-39810.2
12281,Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries,"OBJECTIVE: To assess the cost effectiveness for tuberculosis (TB) screening of high-risk human immunodeficiency virus (HIV) positive pregnant women by using interferon-gamma release assays (IGRAs) compared to the tuberculin skin test (TST) in low TB incidence countries. METHODS: We constructed Markov models using a public health payer perspective. The target population was a hypothetical cohort of 20 year-olds HIV positive pregnant women until age 50 years in three most common screening situations; close contacts, immigrants from high burden countries and occasional screenings. BCG vaccination status was considered. Five strategies; TST, QuantiFERON(R)-TB Gold In-Tube (QFT), T-SPOT(R). TB (T-SPOT), TST followed by QFT and TST followed by T-SPOT were modeled. The main outcome measure of effectiveness was quality-adjusted life-years (QALYs) gained. The incremental cost effectiveness ratio (ICER) of each screening arm was applied and compared. RESULTS: In the base case analyses of close contacts, T-SPOT yielded the greatest benefits at the lowest cost. In the base case analyses of immigrants and occasional screenings, TST followed by QFT yielded the greatest benefits at the lowest cost. CONCLUSIONS: Using an IGRA for TB screening of high-risk HIV positive pregnant women is recommended on the basis of the cost effectiveness in low TB incidence countries.",2014-01-14232,23973660,J Infect,Akiko Kowada,2014,68 / 1,32-42,No,23973660,"Akiko Kowada; Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries, J Infect, ; 68(1):1532-2742; 32-42",QALY,Japan,Not Stated,Not Stated,Tuberculin Skin Test / QuantiFERON - TB Gold In-Tube vs. T-SPOT.Tuberculosis,"pregnant women, Non-BCG vaccinated in postpartum period",50 Years,20 Years,Female,Full,30 Years,3.00,3.00,-35739.85,United States,2012,-40287.92
12282,Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries,"OBJECTIVE: To assess the cost effectiveness for tuberculosis (TB) screening of high-risk human immunodeficiency virus (HIV) positive pregnant women by using interferon-gamma release assays (IGRAs) compared to the tuberculin skin test (TST) in low TB incidence countries. METHODS: We constructed Markov models using a public health payer perspective. The target population was a hypothetical cohort of 20 year-olds HIV positive pregnant women until age 50 years in three most common screening situations; close contacts, immigrants from high burden countries and occasional screenings. BCG vaccination status was considered. Five strategies; TST, QuantiFERON(R)-TB Gold In-Tube (QFT), T-SPOT(R). TB (T-SPOT), TST followed by QFT and TST followed by T-SPOT were modeled. The main outcome measure of effectiveness was quality-adjusted life-years (QALYs) gained. The incremental cost effectiveness ratio (ICER) of each screening arm was applied and compared. RESULTS: In the base case analyses of close contacts, T-SPOT yielded the greatest benefits at the lowest cost. In the base case analyses of immigrants and occasional screenings, TST followed by QFT yielded the greatest benefits at the lowest cost. CONCLUSIONS: Using an IGRA for TB screening of high-risk HIV positive pregnant women is recommended on the basis of the cost effectiveness in low TB incidence countries.",2014-01-14232,23973660,J Infect,Akiko Kowada,2014,68 / 1,32-42,No,23973660,"Akiko Kowada; Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries, J Infect, ; 68(1):1532-2742; 32-42",QALY,Japan,Not Stated,Not Stated,Tuberculin Skin Test / QuantiFERON - TB Gold In-Tube vs. Tuberculin Skin Test / T-SPOT.Tuberculosis,"pregnant women, BCG vaccinated in postpartum period",50 Years,20 Years,Female,Full,30 Years,3.00,3.00,-35688.31,United States,2012,-40229.83
12283,Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries,"OBJECTIVE: To assess the cost effectiveness for tuberculosis (TB) screening of high-risk human immunodeficiency virus (HIV) positive pregnant women by using interferon-gamma release assays (IGRAs) compared to the tuberculin skin test (TST) in low TB incidence countries. METHODS: We constructed Markov models using a public health payer perspective. The target population was a hypothetical cohort of 20 year-olds HIV positive pregnant women until age 50 years in three most common screening situations; close contacts, immigrants from high burden countries and occasional screenings. BCG vaccination status was considered. Five strategies; TST, QuantiFERON(R)-TB Gold In-Tube (QFT), T-SPOT(R). TB (T-SPOT), TST followed by QFT and TST followed by T-SPOT were modeled. The main outcome measure of effectiveness was quality-adjusted life-years (QALYs) gained. The incremental cost effectiveness ratio (ICER) of each screening arm was applied and compared. RESULTS: In the base case analyses of close contacts, T-SPOT yielded the greatest benefits at the lowest cost. In the base case analyses of immigrants and occasional screenings, TST followed by QFT yielded the greatest benefits at the lowest cost. CONCLUSIONS: Using an IGRA for TB screening of high-risk HIV positive pregnant women is recommended on the basis of the cost effectiveness in low TB incidence countries.",2014-01-14232,23973660,J Infect,Akiko Kowada,2014,68 / 1,32-42,No,23973660,"Akiko Kowada; Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries, J Infect, ; 68(1):1532-2742; 32-42",QALY,Japan,Not Stated,Not Stated,Tuberculin Skin Test / QuantiFERON - TB Gold In-Tube vs. QuantiFERON - TB Gold In-Tube,"pregnant women, BCG vaccinated in postpartum period",50 Years,20 Years,Female,Full,30 Years,3.00,3.00,-15066.93,United States,2012,-16984.27
12284,Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries,"OBJECTIVE: To assess the cost effectiveness for tuberculosis (TB) screening of high-risk human immunodeficiency virus (HIV) positive pregnant women by using interferon-gamma release assays (IGRAs) compared to the tuberculin skin test (TST) in low TB incidence countries. METHODS: We constructed Markov models using a public health payer perspective. The target population was a hypothetical cohort of 20 year-olds HIV positive pregnant women until age 50 years in three most common screening situations; close contacts, immigrants from high burden countries and occasional screenings. BCG vaccination status was considered. Five strategies; TST, QuantiFERON(R)-TB Gold In-Tube (QFT), T-SPOT(R). TB (T-SPOT), TST followed by QFT and TST followed by T-SPOT were modeled. The main outcome measure of effectiveness was quality-adjusted life-years (QALYs) gained. The incremental cost effectiveness ratio (ICER) of each screening arm was applied and compared. RESULTS: In the base case analyses of close contacts, T-SPOT yielded the greatest benefits at the lowest cost. In the base case analyses of immigrants and occasional screenings, TST followed by QFT yielded the greatest benefits at the lowest cost. CONCLUSIONS: Using an IGRA for TB screening of high-risk HIV positive pregnant women is recommended on the basis of the cost effectiveness in low TB incidence countries.",2014-01-14232,23973660,J Infect,Akiko Kowada,2014,68 / 1,32-42,No,23973660,"Akiko Kowada; Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries, J Infect, ; 68(1):1532-2742; 32-42",QALY,Japan,Not Stated,Not Stated,Tuberculin Skin Test / QuantiFERON - TB Gold In-Tube vs. T-SPOT.Tuberculosis test,"pregnant women, BCG vaccinated in postpartum period",50 Years,20 Years,Female,Full,30 Years,3.00,3.00,-31204.92,United States,2012,-35175.9
12285,Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries,"OBJECTIVE: To assess the cost effectiveness for tuberculosis (TB) screening of high-risk human immunodeficiency virus (HIV) positive pregnant women by using interferon-gamma release assays (IGRAs) compared to the tuberculin skin test (TST) in low TB incidence countries. METHODS: We constructed Markov models using a public health payer perspective. The target population was a hypothetical cohort of 20 year-olds HIV positive pregnant women until age 50 years in three most common screening situations; close contacts, immigrants from high burden countries and occasional screenings. BCG vaccination status was considered. Five strategies; TST, QuantiFERON(R)-TB Gold In-Tube (QFT), T-SPOT(R). TB (T-SPOT), TST followed by QFT and TST followed by T-SPOT were modeled. The main outcome measure of effectiveness was quality-adjusted life-years (QALYs) gained. The incremental cost effectiveness ratio (ICER) of each screening arm was applied and compared. RESULTS: In the base case analyses of close contacts, T-SPOT yielded the greatest benefits at the lowest cost. In the base case analyses of immigrants and occasional screenings, TST followed by QFT yielded the greatest benefits at the lowest cost. CONCLUSIONS: Using an IGRA for TB screening of high-risk HIV positive pregnant women is recommended on the basis of the cost effectiveness in low TB incidence countries.",2014-01-14232,23973660,J Infect,Akiko Kowada,2014,68 / 1,32-42,No,23973660,"Akiko Kowada; Cost effectiveness of interferon-gamma release assay for TB screening of HIV positive pregnant women in low TB incidence countries, J Infect, ; 68(1):1532-2742; 32-42",QALY,Japan,Not Stated,Not Stated,Tuberculin Skin Test / QuantiFERON - TB Gold In-Tube vs. Tuberculin Skin Test,"pregnant women, BCG vaccinated in postpartum period",50 Years,20 Years,Female,Full,30 Years,3.00,3.00,-28026.6,United States,2012,-31593.12
12286,Is a diabetes pay-for-performance program cost-effective under the National Health Insurance in Taiwan?,"PURPOSE: In October 2001, a pay-for-performance (P4P) program for diabetes was implemented by the National Health Insurance (NHI), a single-payer program, in Taiwan. However, only limited information is available regarding the influence of this program on the patient''s health-related quality of life. The aim of this study was to estimate the costs and consequences of enrolling patients in the P4P program from a single-payer perspective. METHODS: A retrospective observational study of 529 diabetic patients was conducted between 2004 and 2005. The data used in the study were obtained from the National Health Interview Survey (NHIS) in Taiwan. Direct cost data were obtained from NHI claims data, which were linked to respondents in the NHIS using scrambled individual identification. The generic SF36 health instrument was employed to measure the quality-of-life-related health status and transformed into a utility index. Patients enrolled in the P4P program for at least 3 months were categorized as the P4P group. Following propensity score matching, 260 patients were included in the study. Outcomes included life-years, quality-adjusted life-years (QALYs), diabetes-related medical costs, overall medical costs, and incremental cost-effectiveness ratios (ICERs). A single-payer perspective was assumed, and costs were expressed in US dollars. Nonparametric bootstrapping was conducted to estimate confidence intervals for cost-effectiveness ratios. RESULTS: Following matching, no significant difference was noted between two groups with regard to the patients'' age, gender, education, family income, smoking status, BMI, or whether insulin was used. The P4P group had an increase of 0.08 (95 % CI 0.077-0.080) in QALYs, and the additional diabetes-related medical cost was US$422.74 (95 % CI US$413.58-US$435.05), yielding an ICER of US$5413.93 (95 % CI US$5226.83-US$5562.97) per QALY gained. CONCLUSIONS: Our results provides decision makers with valuable information regarding the impact of the P4P program of diabetes care through a direct comparison of equivalent groups of patients receiving regular care. Under the single-payer NHI system, the use of financial incentives under the DM-P4P program may be an effective means to ensure the quality of follow-up treatment.",2014-01-14236,23975377,Qual Life Res,Elise Chia-Hui Tan,2014,23 / 2,687-96,No,23975377,"Elise Chia-Hui Tan; Raoh-Fang Pwu; Duan-Rung Chen; Ming-Chin Yang; Is a diabetes pay-for-performance program cost-effective under the National Health Insurance in Taiwan?, Qual Life Res, ; 23(2):0962-9343; 687-96",QALY,Taiwan,Not Stated,Not Stated,Pay for Performance (P4P) vs. Standard/Usual Care- Non-P4P,Not Stated,Not Stated,19 Years,"Female, Male",Full,2 Years,Not Stated,Not Stated,5413.93,United States,2005,7174.52
12287,Cost-effectiveness of primary prevention implantable cardioverter defibrillator treatment: data from a large clinical registry,"BACKGROUND: Although randomized trials have shown the beneficial effect on survival of an implantable cardioverter defibrillator (ICD) as primary prevention therapy in selected patients, data concerning the cost-effectiveness in routine clinical practice remain scarce. Accordingly, the purpose of this study was to assess the cost-effectiveness of primary prevention ICD implantation in the real world. METHODS: Patients receiving primary prevention single-chamber or dual-chamber ICD implantation at the Leiden University Medical Center were included in the study. Using a Markov model, lifetime cost, life years (LYs), and gained quality-adjusted life years (QALYs) were estimated for device recipients and control patients. Data on mortality, complication rates, and device longevity were retrieved from our center and entered into the Markov model. To account for model assumptions, one-way deterministic and probabilistic sensitivity analyses were performed. Importantly, calculations for the estimated incremental cost-effectiveness rate (ICER) per QALY gained are based on several numbers of assumptions, and accordingly findings may have over- or underestimated the cost-effectiveness of ICD therapy. RESULTS: Primary prevention ICD implantation adds an estimated mean of 2.07 LYs and 1.73 QALYs. Increased lifetime cost for single-chamber and dual-chamber ICD recipients were estimated at euro60,788 and euro64,216, respectively. This resulted for single-chamber ICD recipients, in an estimated ICER of euro35,154 per QALY gained. In dual-chamber ICD recipients, an estimated ICER of euro37,111 per QALY gained was calculated. According to the probabilistic sensitivity analysis, estimated cost per QALY gained are euro35,837 (95% confidence interval [CI]: euro28,368-euro44,460) for single-chamber and euro37,756 (95% CI: euro29,055-euro46,050) for dual-chamber ICDs. CONCLUSIONS: On the basis of data and detailed costs, derived from routine clinical practice, ICD therapy in selected patients with a reduced left ventricular ejection fraction appears to be cost-effective.",2014-01-14286,23998638,Pacing Clin Electrophysiol,Joep Thijssen,2014,37 / 1,25-34,No,23998638,"Joep Thijssen; M Elske van den Akker van Marle; C Jan Willem Borleffs; Johannes B van Rees; Mihaly K de Bie; Enno T van der Velde; Lieselot van Erven; Martin J Schalij; Cost-effectiveness of primary prevention implantable cardioverter defibrillator treatment: data from a large clinical registry, Pacing Clin Electrophysiol, ; 37(1):1540-8159; 25-34",QALY,Netherlands,Not Stated,Not Stated,Single-chamber implantable cardioverter defibrillator (ICD) implantation vs. Conventional pharmacological therapy,Not Stated,Not Stated,19 Years,"Female, Male",Full,Lifetime,4.00,1.50,35154,Euro,2011,56285.98
12288,Cost-effectiveness of primary prevention implantable cardioverter defibrillator treatment: data from a large clinical registry,"BACKGROUND: Although randomized trials have shown the beneficial effect on survival of an implantable cardioverter defibrillator (ICD) as primary prevention therapy in selected patients, data concerning the cost-effectiveness in routine clinical practice remain scarce. Accordingly, the purpose of this study was to assess the cost-effectiveness of primary prevention ICD implantation in the real world. METHODS: Patients receiving primary prevention single-chamber or dual-chamber ICD implantation at the Leiden University Medical Center were included in the study. Using a Markov model, lifetime cost, life years (LYs), and gained quality-adjusted life years (QALYs) were estimated for device recipients and control patients. Data on mortality, complication rates, and device longevity were retrieved from our center and entered into the Markov model. To account for model assumptions, one-way deterministic and probabilistic sensitivity analyses were performed. Importantly, calculations for the estimated incremental cost-effectiveness rate (ICER) per QALY gained are based on several numbers of assumptions, and accordingly findings may have over- or underestimated the cost-effectiveness of ICD therapy. RESULTS: Primary prevention ICD implantation adds an estimated mean of 2.07 LYs and 1.73 QALYs. Increased lifetime cost for single-chamber and dual-chamber ICD recipients were estimated at euro60,788 and euro64,216, respectively. This resulted for single-chamber ICD recipients, in an estimated ICER of euro35,154 per QALY gained. In dual-chamber ICD recipients, an estimated ICER of euro37,111 per QALY gained was calculated. According to the probabilistic sensitivity analysis, estimated cost per QALY gained are euro35,837 (95% confidence interval [CI]: euro28,368-euro44,460) for single-chamber and euro37,756 (95% CI: euro29,055-euro46,050) for dual-chamber ICDs. CONCLUSIONS: On the basis of data and detailed costs, derived from routine clinical practice, ICD therapy in selected patients with a reduced left ventricular ejection fraction appears to be cost-effective.",2014-01-14286,23998638,Pacing Clin Electrophysiol,Joep Thijssen,2014,37 / 1,25-34,No,23998638,"Joep Thijssen; M Elske van den Akker van Marle; C Jan Willem Borleffs; Johannes B van Rees; Mihaly K de Bie; Enno T van der Velde; Lieselot van Erven; Martin J Schalij; Cost-effectiveness of primary prevention implantable cardioverter defibrillator treatment: data from a large clinical registry, Pacing Clin Electrophysiol, ; 37(1):1540-8159; 25-34",QALY,Netherlands,Not Stated,Not Stated,Dual-chamber implantable cardioverter defibrillator (ICD) vs. Conventional pharmacological therapy,Not Stated,Not Stated,41 Years,"Female, Male",Full,Lifetime,4.00,1.50,37111,Euro,2011,59419.39
12289,Cost-effectiveness of MODY genetic testing: translating genomic advances into practical health applications,"OBJECTIVE To evaluate the cost-effectiveness of a genetic testing policy for HNF1A-, HNF4A-, and GCK-MODY in a hypothetical cohort of type 2 diabetic patients 25-40 years old with a MODY prevalence of 2%. RESEARCH DESIGN AND METHODS We used a simulation model of type 2 diabetes complications based on UK Prospective Diabetes Study data, modified to account for the natural history of disease by genetic subtype to compare a policy of genetic testing at diabetes diagnosis versus a policy of no testing. Under the screening policy, successful sulfonylurea treatment of HNF1A-MODY and HNF4A-MODY was modeled to produce a glycosylated hemoglobin reduction of -1.5% compared with usual care. GCK-MODY received no therapy. Main outcome measures were costs and quality-adjusted life years (QALYs) based on lifetime risk of complications and treatments, expressed as the incremental cost-effectiveness ratio (ICER) (USD/QALY). RESULTS The testing policy yielded an average gain of 0.012 QALYs and resulted in an ICER of 205,000 USD. Sensitivity analysis showed that if the MODY prevalence was 6%, the ICER would be ~50,000 USD. If MODY prevalence was >30%, the testing policy was cost saving. Reducing genetic testing costs to 700 USD also resulted in an ICER of ~50,000 USD. CONCLUSIONS Our simulated model suggests that a policy of testing for MODY in selected populations is cost-effective for the U.S. based on contemporary ICER thresholds. Higher prevalence of MODY in the tested population or decreased testing costs would enhance cost-effectiveness. Our results make a compelling argument for routine coverage of genetic testing in patients with high clinical suspicion of MODY.",2014-01-14324,24026547,Diabetes Care,Rochelle N Naylor,2014,37 / 1,202-9,No,24026547,"Rochelle N Naylor; Priya M John; Aaron N Winn; David Carmody; Siri Atma W Greeley; Louis H Philipson; Graeme I Bell; Elbert S Huang; Cost-effectiveness of MODY genetic testing: translating genomic advances into practical health applications, Diabetes Care, ; 37(1):0149-5992; 202-9",QALY,United States of America,Not Stated,Not Stated,"Routine genetic testing for GCK-, HNF1A-, and HNF4A- vs. No genetic testing",Newly diagnosed patients with presumed type 2 diabetes,40 Years,25 Years,"Female, Male",Full,Lifetime,3.00,3.00,205000,United States,2011,235869.52
12290,Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin's lymphoma: cost-effectiveness analyses,"OBJECTIVE: Evaluate the cost-effectiveness of primary vs secondary prophylaxis (PP vs SP) with pegfilgrastim to reduce the risk of febrile neutropenia (FN) in Non-Hodgkin''s Lymphoma (NHL) patients receiving myelosuppressive chemotherapy from a US payer perspective. METHODS: A Markov model was used to compare PP vs SP with pegfilgrastim in a cohort of patients receiving six cycles of cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) or CHOP plus rituximab (CHOP-R) chemotherapy. Model inputs, including efficacy of pegfilgrastim in reducing risk of FN and costs, were estimated from publicly available sources and peer-reviewed publications. Incremental cost-effectiveness was evaluated in terms of net cost per life-year saved (LYS), per quality-adjusted life-year (QALY) gained, and per FN event avoided over a lifetime horizon. Deterministic and probabilistic analyses were performed to assess sensitivity and robustness of results. RESULTS: Lifetime costs for PP were $5000 greater than for SP; however, PP was associated with fewer FN events and more LYs and QALYs gained vs SP. Incremental cost-effectiveness ratios (ICERs) for PP vs SP for CHOP were $13,400 per FN event avoided, $29,500 per QALY gained, and $25,800 per LYS. CHOP-R results were similar ($15,000 per FN event avoided, $33,000 per QALY gained, and $28,900 per LYS). Results were most sensitive to baseline FN risk, cost per FN episode, and odds ratio for reduced relative dose intensity due to prior FN event. PP was cost-effective vs SP in 85% of simulations at a $50,000 per QALY threshold. LIMITATIONS: In the absence of NHL-specific data, estimates for pegfilgrastim efficacy and relative risk reduction of FN were based on available data for neoadjuvant TAC in patients with breast cancer. Baseline risks of FN for CHOP and CHOP-R were assumed to be equivalent. CONCLUSIONS: PP with pegfilgrastim is cost-effective compared to SP with pegfilgrastim in NHL patients receiving CHOP or CHOP-R.",2014-01-14328,24028444,J Med Econ,Gregory Hill,2014,17 / 1,32-42,Yes,24028444,"Gregory Hill; Richard Barron; Kelly Fust; Michelle E Skornicki; Douglas C A Taylor; Milton C Weinstein; Gary H Lyman; Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin's lymphoma: cost-effectiveness analyses, J Med Econ, ; 17(1):1369-6998; 32-42",QALY,United States of America,Not Stated,Not Stated,Primary prophylaxis* with pegfilgrastim vs. Secondary prophylaxis* with pegfilgrastim,"receiving cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP)",66 Years,66 Years,"Female, Male",Full,Lifetime,Not Stated,3.00,29500,United States,2012,33254.02
12291,Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin's lymphoma: cost-effectiveness analyses,"OBJECTIVE: Evaluate the cost-effectiveness of primary vs secondary prophylaxis (PP vs SP) with pegfilgrastim to reduce the risk of febrile neutropenia (FN) in Non-Hodgkin''s Lymphoma (NHL) patients receiving myelosuppressive chemotherapy from a US payer perspective. METHODS: A Markov model was used to compare PP vs SP with pegfilgrastim in a cohort of patients receiving six cycles of cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) or CHOP plus rituximab (CHOP-R) chemotherapy. Model inputs, including efficacy of pegfilgrastim in reducing risk of FN and costs, were estimated from publicly available sources and peer-reviewed publications. Incremental cost-effectiveness was evaluated in terms of net cost per life-year saved (LYS), per quality-adjusted life-year (QALY) gained, and per FN event avoided over a lifetime horizon. Deterministic and probabilistic analyses were performed to assess sensitivity and robustness of results. RESULTS: Lifetime costs for PP were $5000 greater than for SP; however, PP was associated with fewer FN events and more LYs and QALYs gained vs SP. Incremental cost-effectiveness ratios (ICERs) for PP vs SP for CHOP were $13,400 per FN event avoided, $29,500 per QALY gained, and $25,800 per LYS. CHOP-R results were similar ($15,000 per FN event avoided, $33,000 per QALY gained, and $28,900 per LYS). Results were most sensitive to baseline FN risk, cost per FN episode, and odds ratio for reduced relative dose intensity due to prior FN event. PP was cost-effective vs SP in 85% of simulations at a $50,000 per QALY threshold. LIMITATIONS: In the absence of NHL-specific data, estimates for pegfilgrastim efficacy and relative risk reduction of FN were based on available data for neoadjuvant TAC in patients with breast cancer. Baseline risks of FN for CHOP and CHOP-R were assumed to be equivalent. CONCLUSIONS: PP with pegfilgrastim is cost-effective compared to SP with pegfilgrastim in NHL patients receiving CHOP or CHOP-R.",2014-01-14328,24028444,J Med Econ,Gregory Hill,2014,17 / 1,32-42,Yes,24028444,"Gregory Hill; Richard Barron; Kelly Fust; Michelle E Skornicki; Douglas C A Taylor; Milton C Weinstein; Gary H Lyman; Primary vs secondary prophylaxis with pegfilgrastim for the reduction of febrile neutropenia risk in patients receiving chemotherapy for non-Hodgkin's lymphoma: cost-effectiveness analyses, J Med Econ, ; 17(1):1369-6998; 32-42",QALY,United States of America,Not Stated,Not Stated,Primary prophylaxis* with pegfilgrastim vs. Secondary prophylaxis** with pegfilgrastim *,"receiving cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) plus rituximab (CHOP-R)",66 Years,66 Years,"Female, Male",Full,Lifetime,Not Stated,3.00,33000,United States,2012,37199.42
12292,Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients,"BACKGROUND: Telaprevir (TVR,T) and boceprevir (BOC,B) are direct-acting antivirals (DAAs) used for the treatment of chronic genotype 1 hepatitis C virus (HCV) infection. This analysis evaluated the cost-effectiveness of TVR combined with pegylated interferon (Peg-IFN) alfa-2a plus ribavirin (RBV) compared with Peg-IFN alfa-2a and RBV (PR) alone or BOC plus Peg-IFN alfa-2b and RBV in treatment-experienced patients. METHODS: A Markov cohort model of chronic genotype 1 HCV disease progression reflected the pathway of experienced patients retreated with DAA therapy. The population was stratified by previous response to treatment (i.e., previous relapsers, partial responders, and null responders). Sustained virologic response (SVR) rates were derived from a mixed-treatment comparison that included results from separate Phase III trials of TVR and BOC. Incremental cost per life year (LY) gained and quality-adjusted-life-year (QALY) gained were computed at lifetime, adopting the NHS perspective. Costs and health outcomes were discounted at 3.5%. Uncertainty was assessed using deterministic and probabilistic sensitivity analyses. Sub-group analyses were carried out by interleukin (IL)-28B genotype. RESULTS: Higher costs and improved outcomes were associated with T/PR relative to PR alone for all experienced patients (ICER of pound6079). T/PR was cost-effective for each sub-group population with high SVR advantage in relapsers (ICER of pound2658 vs pound7593 and pound20,875 for partial and null responders). T/PR remained cost-effective regardless of IL-28B sub-type. Compared to B/PR, T/PR prolonged QALYs by 0.57 and reduced lifetime costs by pound13,960 for relapsers. For partial responders T/PR was less costly but less efficacious than B/PR, equating to an ICER of pound128,117 per QALY gained. LIMITATIONS: No head-to-head trial provides direct evidence of better efficacy of T/PR vs B/PR. CONCLUSION: T/PR is cost-effective compared with PR alone in experienced patients regardless of treatment history and IL-28B genotype. Compared to B/PR, T/PR is always cost-saving but only more effective in relapsers.",2014-01-14336,24032626,J Med Econ,Sandrine Cure,2014,17 / 1,77-87,Yes,24032626,"Sandrine Cure; Florence Bianic; Sandra Gavart; Steve Curtis; Seina Lee; Geoffrey Dusheiko; Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients, J Med Econ, ; 17(1):1369-6998; 77-87",QALY,United Kingdom,Not Stated,Not Stated,Telaprevir + pegylated interferon alpha 2a + ribavirin (T/PR) vs. Pegylated interferon alpha 2a + ribavirn (PR) alone treatment dual therapy for 48 weeks,Not Stated,Not Stated,19 Years,"Female, Male",Full,Lifetime,3.50,3.50,6079,United Kingdom,2010,11138.68
12293,Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients,"BACKGROUND: Telaprevir (TVR,T) and boceprevir (BOC,B) are direct-acting antivirals (DAAs) used for the treatment of chronic genotype 1 hepatitis C virus (HCV) infection. This analysis evaluated the cost-effectiveness of TVR combined with pegylated interferon (Peg-IFN) alfa-2a plus ribavirin (RBV) compared with Peg-IFN alfa-2a and RBV (PR) alone or BOC plus Peg-IFN alfa-2b and RBV in treatment-experienced patients. METHODS: A Markov cohort model of chronic genotype 1 HCV disease progression reflected the pathway of experienced patients retreated with DAA therapy. The population was stratified by previous response to treatment (i.e., previous relapsers, partial responders, and null responders). Sustained virologic response (SVR) rates were derived from a mixed-treatment comparison that included results from separate Phase III trials of TVR and BOC. Incremental cost per life year (LY) gained and quality-adjusted-life-year (QALY) gained were computed at lifetime, adopting the NHS perspective. Costs and health outcomes were discounted at 3.5%. Uncertainty was assessed using deterministic and probabilistic sensitivity analyses. Sub-group analyses were carried out by interleukin (IL)-28B genotype. RESULTS: Higher costs and improved outcomes were associated with T/PR relative to PR alone for all experienced patients (ICER of pound6079). T/PR was cost-effective for each sub-group population with high SVR advantage in relapsers (ICER of pound2658 vs pound7593 and pound20,875 for partial and null responders). T/PR remained cost-effective regardless of IL-28B sub-type. Compared to B/PR, T/PR prolonged QALYs by 0.57 and reduced lifetime costs by pound13,960 for relapsers. For partial responders T/PR was less costly but less efficacious than B/PR, equating to an ICER of pound128,117 per QALY gained. LIMITATIONS: No head-to-head trial provides direct evidence of better efficacy of T/PR vs B/PR. CONCLUSION: T/PR is cost-effective compared with PR alone in experienced patients regardless of treatment history and IL-28B genotype. Compared to B/PR, T/PR is always cost-saving but only more effective in relapsers.",2014-01-14336,24032626,J Med Econ,Sandrine Cure,2014,17 / 1,77-87,Yes,24032626,"Sandrine Cure; Florence Bianic; Sandra Gavart; Steve Curtis; Seina Lee; Geoffrey Dusheiko; Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients, J Med Econ, ; 17(1):1369-6998; 77-87",QALY,United Kingdom,Not Stated,Not Stated,Telaprevir + pegylated interferon alpha 2a + ribavirin (T/PR) vs. Pegylated interferon alpha 2a + ribavirn (PR) alone treatment dual therapy for 48 weeks,Not Stated,Not Stated,19 Years,"Female, Male",Full,Lifetime,3.50,3.50,2658,United Kingdom,2010,4870.31
12294,Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients,"BACKGROUND: Telaprevir (TVR,T) and boceprevir (BOC,B) are direct-acting antivirals (DAAs) used for the treatment of chronic genotype 1 hepatitis C virus (HCV) infection. This analysis evaluated the cost-effectiveness of TVR combined with pegylated interferon (Peg-IFN) alfa-2a plus ribavirin (RBV) compared with Peg-IFN alfa-2a and RBV (PR) alone or BOC plus Peg-IFN alfa-2b and RBV in treatment-experienced patients. METHODS: A Markov cohort model of chronic genotype 1 HCV disease progression reflected the pathway of experienced patients retreated with DAA therapy. The population was stratified by previous response to treatment (i.e., previous relapsers, partial responders, and null responders). Sustained virologic response (SVR) rates were derived from a mixed-treatment comparison that included results from separate Phase III trials of TVR and BOC. Incremental cost per life year (LY) gained and quality-adjusted-life-year (QALY) gained were computed at lifetime, adopting the NHS perspective. Costs and health outcomes were discounted at 3.5%. Uncertainty was assessed using deterministic and probabilistic sensitivity analyses. Sub-group analyses were carried out by interleukin (IL)-28B genotype. RESULTS: Higher costs and improved outcomes were associated with T/PR relative to PR alone for all experienced patients (ICER of pound6079). T/PR was cost-effective for each sub-group population with high SVR advantage in relapsers (ICER of pound2658 vs pound7593 and pound20,875 for partial and null responders). T/PR remained cost-effective regardless of IL-28B sub-type. Compared to B/PR, T/PR prolonged QALYs by 0.57 and reduced lifetime costs by pound13,960 for relapsers. For partial responders T/PR was less costly but less efficacious than B/PR, equating to an ICER of pound128,117 per QALY gained. LIMITATIONS: No head-to-head trial provides direct evidence of better efficacy of T/PR vs B/PR. CONCLUSION: T/PR is cost-effective compared with PR alone in experienced patients regardless of treatment history and IL-28B genotype. Compared to B/PR, T/PR is always cost-saving but only more effective in relapsers.",2014-01-14336,24032626,J Med Econ,Sandrine Cure,2014,17 / 1,77-87,Yes,24032626,"Sandrine Cure; Florence Bianic; Sandra Gavart; Steve Curtis; Seina Lee; Geoffrey Dusheiko; Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients, J Med Econ, ; 17(1):1369-6998; 77-87",QALY,United Kingdom,Not Stated,Not Stated,Telaprevir + pegylated interferon alpha 2a + ribavirin (T/PR) vs. Pegylated interferon alpha 2a + ribavirn (PR) alone treatment dual therapy for 48 weeks,Not Stated,Not Stated,19 Years,"Female, Male",Full,Lifetime,3.50,3.50,7593,United Kingdom,2010,13912.82
12295,Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients,"BACKGROUND: Telaprevir (TVR,T) and boceprevir (BOC,B) are direct-acting antivirals (DAAs) used for the treatment of chronic genotype 1 hepatitis C virus (HCV) infection. This analysis evaluated the cost-effectiveness of TVR combined with pegylated interferon (Peg-IFN) alfa-2a plus ribavirin (RBV) compared with Peg-IFN alfa-2a and RBV (PR) alone or BOC plus Peg-IFN alfa-2b and RBV in treatment-experienced patients. METHODS: A Markov cohort model of chronic genotype 1 HCV disease progression reflected the pathway of experienced patients retreated with DAA therapy. The population was stratified by previous response to treatment (i.e., previous relapsers, partial responders, and null responders). Sustained virologic response (SVR) rates were derived from a mixed-treatment comparison that included results from separate Phase III trials of TVR and BOC. Incremental cost per life year (LY) gained and quality-adjusted-life-year (QALY) gained were computed at lifetime, adopting the NHS perspective. Costs and health outcomes were discounted at 3.5%. Uncertainty was assessed using deterministic and probabilistic sensitivity analyses. Sub-group analyses were carried out by interleukin (IL)-28B genotype. RESULTS: Higher costs and improved outcomes were associated with T/PR relative to PR alone for all experienced patients (ICER of pound6079). T/PR was cost-effective for each sub-group population with high SVR advantage in relapsers (ICER of pound2658 vs pound7593 and pound20,875 for partial and null responders). T/PR remained cost-effective regardless of IL-28B sub-type. Compared to B/PR, T/PR prolonged QALYs by 0.57 and reduced lifetime costs by pound13,960 for relapsers. For partial responders T/PR was less costly but less efficacious than B/PR, equating to an ICER of pound128,117 per QALY gained. LIMITATIONS: No head-to-head trial provides direct evidence of better efficacy of T/PR vs B/PR. CONCLUSION: T/PR is cost-effective compared with PR alone in experienced patients regardless of treatment history and IL-28B genotype. Compared to B/PR, T/PR is always cost-saving but only more effective in relapsers.",2014-01-14336,24032626,J Med Econ,Sandrine Cure,2014,17 / 1,77-87,Yes,24032626,"Sandrine Cure; Florence Bianic; Sandra Gavart; Steve Curtis; Seina Lee; Geoffrey Dusheiko; Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients, J Med Econ, ; 17(1):1369-6998; 77-87",QALY,United Kingdom,Not Stated,Not Stated,Telaprevir + pegylated interferon alpha 2a + ribavirin (T/PR) vs. Pegylated interferon alpha 2a + ribavirn (PR) alone treatment dual therapy for 48 weeks,Not Stated,Not Stated,19 Years,"Female, Male",Full,Lifetime,3.50,3.50,20875,United Kingdom,2010,38249.71
12296,Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients,"BACKGROUND: Telaprevir (TVR,T) and boceprevir (BOC,B) are direct-acting antivirals (DAAs) used for the treatment of chronic genotype 1 hepatitis C virus (HCV) infection. This analysis evaluated the cost-effectiveness of TVR combined with pegylated interferon (Peg-IFN) alfa-2a plus ribavirin (RBV) compared with Peg-IFN alfa-2a and RBV (PR) alone or BOC plus Peg-IFN alfa-2b and RBV in treatment-experienced patients. METHODS: A Markov cohort model of chronic genotype 1 HCV disease progression reflected the pathway of experienced patients retreated with DAA therapy. The population was stratified by previous response to treatment (i.e., previous relapsers, partial responders, and null responders). Sustained virologic response (SVR) rates were derived from a mixed-treatment comparison that included results from separate Phase III trials of TVR and BOC. Incremental cost per life year (LY) gained and quality-adjusted-life-year (QALY) gained were computed at lifetime, adopting the NHS perspective. Costs and health outcomes were discounted at 3.5%. Uncertainty was assessed using deterministic and probabilistic sensitivity analyses. Sub-group analyses were carried out by interleukin (IL)-28B genotype. RESULTS: Higher costs and improved outcomes were associated with T/PR relative to PR alone for all experienced patients (ICER of pound6079). T/PR was cost-effective for each sub-group population with high SVR advantage in relapsers (ICER of pound2658 vs pound7593 and pound20,875 for partial and null responders). T/PR remained cost-effective regardless of IL-28B sub-type. Compared to B/PR, T/PR prolonged QALYs by 0.57 and reduced lifetime costs by pound13,960 for relapsers. For partial responders T/PR was less costly but less efficacious than B/PR, equating to an ICER of pound128,117 per QALY gained. LIMITATIONS: No head-to-head trial provides direct evidence of better efficacy of T/PR vs B/PR. CONCLUSION: T/PR is cost-effective compared with PR alone in experienced patients regardless of treatment history and IL-28B genotype. Compared to B/PR, T/PR is always cost-saving but only more effective in relapsers.",2014-01-14336,24032626,J Med Econ,Sandrine Cure,2014,17 / 1,77-87,Yes,24032626,"Sandrine Cure; Florence Bianic; Sandra Gavart; Steve Curtis; Seina Lee; Geoffrey Dusheiko; Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients, J Med Econ, ; 17(1):1369-6998; 77-87",QALY,United Kingdom,Not Stated,Not Stated,Telaprevir + pegylated interferon alpha 2a + ribavirin (T/PR) vs. Boceprevir + pegylated interferon alpha 2a + ribavirin(B/PR),Not Stated,Not Stated,19 Years,"Female, Male",Full,Lifetime,3.50,3.50,-24491.23,United Kingdom,2010,-44875.81
12297,Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients,"BACKGROUND: Telaprevir (TVR,T) and boceprevir (BOC,B) are direct-acting antivirals (DAAs) used for the treatment of chronic genotype 1 hepatitis C virus (HCV) infection. This analysis evaluated the cost-effectiveness of TVR combined with pegylated interferon (Peg-IFN) alfa-2a plus ribavirin (RBV) compared with Peg-IFN alfa-2a and RBV (PR) alone or BOC plus Peg-IFN alfa-2b and RBV in treatment-experienced patients. METHODS: A Markov cohort model of chronic genotype 1 HCV disease progression reflected the pathway of experienced patients retreated with DAA therapy. The population was stratified by previous response to treatment (i.e., previous relapsers, partial responders, and null responders). Sustained virologic response (SVR) rates were derived from a mixed-treatment comparison that included results from separate Phase III trials of TVR and BOC. Incremental cost per life year (LY) gained and quality-adjusted-life-year (QALY) gained were computed at lifetime, adopting the NHS perspective. Costs and health outcomes were discounted at 3.5%. Uncertainty was assessed using deterministic and probabilistic sensitivity analyses. Sub-group analyses were carried out by interleukin (IL)-28B genotype. RESULTS: Higher costs and improved outcomes were associated with T/PR relative to PR alone for all experienced patients (ICER of pound6079). T/PR was cost-effective for each sub-group population with high SVR advantage in relapsers (ICER of pound2658 vs pound7593 and pound20,875 for partial and null responders). T/PR remained cost-effective regardless of IL-28B sub-type. Compared to B/PR, T/PR prolonged QALYs by 0.57 and reduced lifetime costs by pound13,960 for relapsers. For partial responders T/PR was less costly but less efficacious than B/PR, equating to an ICER of pound128,117 per QALY gained. LIMITATIONS: No head-to-head trial provides direct evidence of better efficacy of T/PR vs B/PR. CONCLUSION: T/PR is cost-effective compared with PR alone in experienced patients regardless of treatment history and IL-28B genotype. Compared to B/PR, T/PR is always cost-saving but only more effective in relapsers.",2014-01-14336,24032626,J Med Econ,Sandrine Cure,2014,17 / 1,77-87,Yes,24032626,"Sandrine Cure; Florence Bianic; Sandra Gavart; Steve Curtis; Seina Lee; Geoffrey Dusheiko; Cost-effectiveness of telaprevir in combination with pegylated interferon alpha and ribavirin in treatment-experienced chronic hepatitis C genotype 1 patients, J Med Econ, ; 17(1):1369-6998; 77-87",QALY,United Kingdom,Not Stated,Not Stated,Telaprevir + pegylated interferon alpha 2a + ribavirin (T/PR) vs. Boceprevir + pegylated interferon alpha 2a + ribavirin (B/PR),Not Stated,Not Stated,19 Years,"Female, Male",Full,Lifetime,3.50,3.50,128116.67,United Kingdom,2010,234750.95
12298,Cost-effectiveness analysis of scalp cooling to reduce chemotherapy-induced alopecia,"BACKGROUND: Alopecia is a frequently occurring side effect of chemotherapy that often can be prevented by cooling the scalp during the infusion. This study compared effects and costs of scalp cooling with usual general oncological care, i.e. purchasing a wig or head cover. MATERIAL AND METHODS: Scalp-cooled patients (n = 160) were compared with non-scalp-cooled patients (n = 86) at 15 Dutch hospitals. Patients were enrolled prior to anthracycline and/or taxane-based chemotherapy for several types of cancer between 2007 and 2008. Cost-effectiveness of scalp cooling compared with that of usual care was determined by the ratio of costs to quality adjusted life years (QALYs). Costs for scalp cooling (machines and nursing time), hair dressers, wigs and head covers were estimated from a societal perspective. QALYs were measured using the Short Form-36. RESULTS: Scalp cooling reduced the use of a wig or head cover by 40%, but wigs were still purchased unnecessarily by 38% of scalp-cooled patients. Average societal costs decreased therefore only by euro269 per patient due to scalp cooling (p = 0.02). Given the eligibility for scalp cooling at the time, the insignificant difference in QALYs resulted from a balance of the benefits for those patients with successful scalp cooling and those without success. For the Dutch, given the generally accepted threshold of willingness to pay for a QALY (between euro20 000 and euro40 000), scalp cooling was cost-effective, therefore justifying the choice of scalp cooling or purchasing a wig or head cover. CONCLUSION: Given the right indication, cost-effectiveness might be improved further by postponing wig and head cover purchases, by improving scalp cooling efficacy, as well as using the scalp cooling capacity more intensively.",2014-01-14403,24059270,Acta Oncol,Corina J van den Hurk,2014,53 / 1,80-7,No,24059270,"Corina J van den Hurk; M Elske van den Akker-van Marle; Wim P Breed; Lonneke V van de Poll-Franse; Johan W Nortier; Jan W Coebergh; Cost-effectiveness analysis of scalp cooling to reduce chemotherapy-induced alopecia, Acta Oncol, ; 53(1):0284-186X; 80-7",QALY,Netherlands,Not Stated,Not Stated,"Scalp cooling: performed using the Paxman system (type PSC1 or PSC2) vs. ""Usual (oncological) care, i.e. in the Netherlands the choice of purchasing a wig or head cover, when cancer patients are faced with chemotherapy-induced alopecia (CIA)""",Not Stated,77 Years,28 Years,"Female, Male",Full,1 Year,Not Stated,Not Stated,34000,Euro,2010,53406.84
12299,Cost effectiveness of endosonography versus surgical staging in potentially resectable lung cancer: a health economics analysis of the ASTER trial from a European perspective,"In the ASTER study, mediastinal staging was more accurate for patients randomised to combined endobronchial and endoscopic ultrasound, followed by surgical staging if endoscopy was negative, versus surgical staging alone. Here, we report survival, quality of life and cost effectiveness up to 6 months, for the UK, The Netherlands and Belgium, separately. Survival in the two arms of the study was similar. In all three countries, the endosonography strategy had slightly higher quality-adjusted life years over 6 months, and was cheaper. Therefore, based on clinical accuracy and cost effectiveness, we conclude that mediastinal staging should commence with endosonography.",2014-01-14412,24064440,Thorax,Robert C Rintoul,2014,69 / 7,679-81,No,24064440,"Robert C Rintoul; Matthew J Glover; Christopher Jackson; Victoria Hughes; Kurt G Tournoy; Christophe Dooms; Jouke T Annema; Linda D Sharples; Cost effectiveness of endosonography versus surgical staging in potentially resectable lung cancer: a health economics analysis of the ASTER trial from a European perspective, Thorax, ; 69(7):0040-6376; 679-81",QALY,United Kingdom,Not Stated,Not Stated,Combined endoscopic and endobronchial ultrasound followed by surgical staging (if no nodal metastases were found at endosonography vs. Surgical staging alone,Not Stated,Not Stated,19 Years,"Female, Male",Full,6 Months,Not Stated,Not Stated,-67333.34,Euro,2011,-107809.15
12300,Cost effectiveness of endosonography versus surgical staging in potentially resectable lung cancer: a health economics analysis of the ASTER trial from a European perspective,"In the ASTER study, mediastinal staging was more accurate for patients randomised to combined endobronchial and endoscopic ultrasound, followed by surgical staging if endoscopy was negative, versus surgical staging alone. Here, we report survival, quality of life and cost effectiveness up to 6 months, for the UK, The Netherlands and Belgium, separately. Survival in the two arms of the study was similar. In all three countries, the endosonography strategy had slightly higher quality-adjusted life years over 6 months, and was cheaper. Therefore, based on clinical accuracy and cost effectiveness, we conclude that mediastinal staging should commence with endosonography.",2014-01-14412,24064440,Thorax,Robert C Rintoul,2014,69 / 7,679-81,No,24064440,"Robert C Rintoul; Matthew J Glover; Christopher Jackson; Victoria Hughes; Kurt G Tournoy; Christophe Dooms; Jouke T Annema; Linda D Sharples; Cost effectiveness of endosonography versus surgical staging in potentially resectable lung cancer: a health economics analysis of the ASTER trial from a European perspective, Thorax, ; 69(7):0040-6376; 679-81",QALY,Netherlands,Not Stated,Not Stated,Combined endoscopic and endobronchial ultrasound followed by surgical staging (if no nodal metastases were found at endosonography). vs. Surgical staging alone,Not Stated,Not Stated,19 Years,"Female, Male",Full,6 Months,Not Stated,Not Stated,-9200,Euro,2011,-14730.36
